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ABSTRACT 
 
The studies presented in this thesis aimed to investigate the regulation of the cysteine protease 
legumain in various human cells (paper I-IV), effects of statins (paper II and III) and a 
legumain-cleavable colchicine prodrug (paper IV). Legumain is the only known asparaginyl 
endoprotease and shows high structural similarities to the caspases. Legumain is reported to 
participate in extracellular matrix degradation by processing of pro-matrix metalloprotase-2, 
fibronectin, cathepsin B and L. The subcellular localization of legumain is thought to be 
mainly lysosomal, and dysregulation of legumain is suggested to be of consequence for 
proteolytic degradation and tissue remodeling. High legumain expression is correlated with 
cancer progression and malignancy as well as atherosclerotic plaque rupture, and 
pharmacological intervention targeting legumain may be useful. 
In the present work, legumain and/or cystatin E/M over-expressing HEK293 cells 
were established, and used to study regulation, subcellular localization and interplay of 
legumain and cystatin E/M (paper I). Legumain over-expressing HEK293 cells secreted 
prolegumain that was able to be internalized and subsequently activated intracellularly (paper 
I). Cystatin E/M (the most potent endogenous inhibitor of legumain) was also secreted and 
internalized, and thus able to regulate legumain activity both intra- and extracellularly (paper 
I). Macrophages are key regulators in cancer and atherosclerosis. In paper II, legumain 
expression, activity and secretion were highly up-regulated during monocyte-to-macrophage 
differentiation (paper II). Interestingly, 90 % of the legumain produced in M-CSF-stimulated 
macrophages was secreted as prolegumain, and surprisingly legumain was detected in human 
sera (paper II). Secreted legumain points to extracellular functions, and quantification may 
have diagnostic or prognostic value.  
Statins (HMG-CoA reductase inhibitors) have so-called pleiotropic effects beyond 
lowering the serum cholesterol level. These drugs are generally well tolerated, although 
skeletal muscle side effects are known, especially by simvastatin. In monocytes from patients 
treated with atorvastatin, legumain mRNA is shown to be down-regulated. Herein, statins 
were shown to inhibited legumain activity, expression, processing and secretion in various 
human cells types, such as macrophages (paper II), myotubes (paper III), and in legumain 
over-expressing HEK293 cells (Fig. 8), probably by interfering with the intracellular vesicular 
trafficking or by increasing the pH of the lysosomes (paper III). Legumain inhibition may 
contribute to the pleiotropic effects of statins.  
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A novel pharmacological strategy is to construct a prodrug of a cytotoxic drug 
conjugated with a legumain-cleavable peptide (Ala-Ala-Asn), which upon cleavage by 
legumain becomes cytotoxic to legumain over-expressing cancer cells and tissues.
In paper IV, a novel legumain-cleavable colchicine prodrug (Suc-Ala-Ala-Asn-Val-
colchicine) were synthesized and showed cell-specific toxicity towards cells expressing active 
legumain (legumain over-expressing HEK293 cells and HCT116 colorectal cancer cell). 
 In conclusion, the studies presented in this thesis have contributed to new knowledge 
about regulation of the cysteine protease legumain. It has demonstrated that regulation of 
legumain occur both extra- and intracellular by cystatin E/M. Pharmacological inhibition of 
legumain by statins or by utilizing legumain to release cytotoxic colchicine from a legumain-
cleavable prodrug may be of therapeutic value in preventing morbidity and mortality in cancer 
and atherosclerosis. 
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INTRODUCTION 
 
Proteolytic enzymes 
 
Synthesis and degradation of proteins are essential for life and proper cellular function. 
Approximately 2 % of the functional genes in the human genome encode for proteolytic 
enzymes (proteases, peptidases or proteinases) [1]. Proteolysis is cleavage of the polypeptide 
chain by irreversible hydrolysis (nucleophilic attack) of the peptide bonds within the 
substrate. Exoproteases cleave at the C- or N-terminal end of a polypeptide chain resulting in 
release of either a single peptide or dipeptide, whereas endoproteases cleave internally in the 
polypeptide chain. The database MEROPS classifies proteases based on their proteolytical 
mechanisms (classes), evolutionary relationship defined by their globular three-dimensional 
(3D) folding (clans), and their amino acid sequence homologies (families) [2]. Four major 
classes of mammalian proteases are identified; aspartate, cysteine, serine and metalloproteases 
(Fig. 1). For the serine and cysteine proteases a distinct amino acid serves as the nucleophile 
(serine and cysteine, respectively), whereas for the aspartate and metalloproteases a water 
molecule is responsible for the proteolysis. To perform proteolysis, both serine and cysteine 
proteases requires a second amino residue, a proton donor (histidine). In addition, many 
families of cysteine proteases (e.g. family C1, C2) also have an additional third catalytic 
residue to orientate the imidazolium ring of the histidine.  
A protease clan is defined as a group of families for which there are indications of an 
evolutionary relationship despite the lack of significant similarities in the sequences. Such 
relationship comes from similar linear arrangements of active site residues in the sequences or 
from similar protein folds (secondary or tertiary structure, respectively). The clans are named 
with two letters; the first letter is given by the catalytic type and the second letter 
distinguishes the clans by alphabetic order (e.g. clan CA, CD; Fig. 1). In each clan one or 
more protease families are included. A set of homologous proteases with significant similarity 
in the amino acid sequences (primary structure) is referred to as a protease family. The 
nomenclature of a protease family is represented by a letter followed by a number. The letter 
represents the catalytic type of the protease, whereas the number distinguishes the families in 
a numbered order (e.g. C13, C14; Fig. 1) [2].  
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Figure 1. Classification of mammalian proteases according to MEROPS. Proteases are classified 
based on catalytic mechanisms and structure similarities. The proteases are first classified based on 
their catalytic type, hence aspartate, cysteine, metallo or serine (orange boxes). The proteases are 
further divided into clans (blue boxes) based on common evolutionary origins such as similar 3D 
protein structures or the order of amino acids comprising the catalytic part of the polypeptide chain. 
Each clan is further divided into one or more protease families (red boxes) based on high similarity in 
the amino acid sequences. Modified from [2]. 
 
Cysteine proteases 
 
The first recognized cysteine protease was papain, found in the latex of the tropical papaya 
fruit. This enzyme is the archetype of the cysteine proteases and belongs to the clan CA, 
family C1. The mammalian analogs of papain are the cysteine cathepsins (cathepsin B, C 
(dipeptidyl-peptidase I), F, H, K, L, O, S, V, W and X; Fig. 1). Although most of the 
cathepsins are cysteine proteases, it is noteworthy to mention that cathepsin D and E are 
aspartic proteases, and cathepsin A and G are serine proteases [2]. In the following text, 
cathepsins refer to the cysteine cathepsins. In addition, the calpains, legumain and caspases 
are other cysteine proteases. The calpains belongs to the clan CA, family C2, and are 
dependent of a neutral environment, reducing conditions and calcium ions to acquire activity. 
Legumain (C13 family) and the caspases (C14 family) belong to clan CD, and will be 
addressed below.  
Proteases 
Aspartate 
Cysteine 
Clan CA 
Family C1 
Cathepsin B, F, H, 
K, L, O, S, V, W 
and  X  
Family C2 
Calpains 
Clan CD 
Family C13 
Legumain 
Family C14 
Caspases 
Metallo 
Serine 
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The Schechter and Berger nomenclature model can be used to describe the interaction 
between the active site of an endoprotease and its peptide substrate [3]. The model divides the 
active site of the endoprotease into substrate-binding subsites (numbered S4, S3, S2, S1, S`1, 
S`2 and S`3) which binds the corresponding amino acids of the substrate (numbered P4, P3, 
P2, P1, P`1, P`2 and P`3), respectively [3]. The substrate-binding subsites are located on both 
sites of the catalytic site; the non-primed subsites are located on the N-terminal end of the 
substrate and the S1 subsite is nearest the catalytic site. The primed subsites are located on the 
C-terminal end of the substrate and S`1 is nearest the catalytic site.  
The cysteine proteases are synthesized as inactive precursors (preproforms/proforms) 
and require a biochemical change such as hydrolysis to reveal its catalytic site. Hydrolysis of 
the inactive precursors can be facilitated either by other proteases or by auto-activation [4-6]. 
The precursors are normally cleaved in the endoplasmic reticulum (ER) and transported to the 
acidic endosomes/lysosomes and auto-activated. Auto-activation can therefore be regulated 
by post-translational modifications of cysteine proteases affecting the transport to the 
lysosomes. Interestingly, glycosaminoglycans (GAGs) have shown properties for accelerating 
the activation process of cysteine proteases [7-9]. Both the auto-activation and activity of 
cysteine proteases can be regulated by inhibitors such as the cystatins [10, 11] and the 
proteases require a reductive environment to achieve activity. 
Cysteine cathepsins 
The name “cathepsin” is from ancient Greek meaning degrade or “boil down” (kata, down; 
hepsein, boil). Cysteine cathepsins share a conserved active site which is formed by a 
catalytic triad consisting of cysteine, histidine and asparagine residues. Cathepsins have three 
well-defined substrate-binding subsites (S2, S1 and S1`) [12]. Cathepsin B represents the first 
described mammalian member of the C1 family and needs low pH for optimal activity (Table 
1) [13]. Interestingly, some cathepsins also show activity in neutral environment [14, 15]. 
Most members of the cathepsins are endoproteases except dipeptidyl-peptidase I (previously 
named cathepsin C) and cathepsin X which are exoproteases. However, cathepsin B and H 
exert both exoprotease and endoprotease activities. The proteolytical active forms of 
cathepsin B, H and L are expressed as single and two-chain forms. The two-chain form is 
possibly due to intramolecular S-S-bridging. Most of the cathepsins are ubiquitously 
expressed and initially believed to be unspecific proteases in protein turnover. Many 
cathepsins share redundant substrate specificity, meaning that function loss of one particular 
enzyme does not necessarily lead to changes in cellular functions or a characteristic 
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phenotype. In gene knock-out (KO) studies both cathepsin B and L KO mice were born 
fertile. Cathepsin L KO mice show retarded hair growth and develop hair loss [16], and 
cathepsin B KO mice develop normally without any apparent neurological or behavioral 
deficits [17]. However, studies on specialized cells revealed predominantly expression of 
certain cathepsins. For example, cathepsin K seems to be important for bone remodeling and 
cathepsin K KO mice develop osteopetrosis, elevated numbers of osteoclasts, regions of 
disorganized bone microstructure and increased bone fragility [18]. Also, cathepsin S seems 
to be involved in antigen presentation since dendritic cells from cathepsin S KO mice have 
reduced cleavage of the invariant chain leading to decreased antigen presentation by the major 
histocompatibility complex (MHC) class II [19].  
Legumain 
Legumain, a lysosomal asparaginyl endoprotease (AEP), is well-conserved throughout 
evolution and belongs to the clan CD, family C13 of cysteine proteases (Fig. 1) [2]. It was 
first discovered in germinating bean cotyledons of kidney beans, which is a part of the plant 
embryo within the plant seed. Later, legumain has been identified in several other plant seeds 
[20-24]. The amino acid sequence of legumain from castor beans was shown to be 
homologous with an enzyme from the fluke Schistosoma mansoni [25], which later was 
reported to have AEP-activity [26]. The AEP discovered by Csoma & Polgár was named 
“legumain” by NC-IUBMB (1992) because of its abundance in seeds from the Fabeceae plant 
family (legume) [24]. In 1997 human expressed sequence tags (EST) were shown to be 
homologous with legumain from plants and Schistosoma mansoni, and human legumain 
cDNA was cloned [27]. The human legumain gene (LGMN) is localized on chromosome 
14q32.1, and the legumain protein consists of 433 amino acids [27, 28]. The human legumain 
shares 30-35 % amino acid sequence homology with legumain from Schistosoma mansoni 
and plants [27].  
Legumain isolated from pig kidney showed AEP-activity that was inhibited by 
ovocystatin (cystatin from chicken egg white) [27]. Legumain shows proteolytic activity for 
substrates rich on asparagine (Asn) in their side chains, and the activity is lost by blocking the 
thiol group (by e.g. iodoacetate), thus confirming that legumain is a cysteine protease [24]. 
Legumain is different from the cysteine cathepsins due to the strict requirement of one 
particular amino acid (asparagine, Asn) in the P1 position [24]. In contrast to the cathepsins, 
legumain do not have other well-defined substrate-binding surrounding subsites except the S1 
site for Asn. What also distinguishes legumain from the C1 and C2 families of cysteine 
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proteases is the lack of inhibition by the cysteine protease inhibitor E-64 or leupeptin [22, 27]. 
The activity and stability of legumain are shown to be pH-dependent; legumain has a catalytic 
optimum at approximately pH 6 and is unstable at pH-values above 6 [27]. Initially, legumain 
was reported to have absolute substrate specificity towards Asn, however, legumain can also 
cleave after aspartate (Asp) residues at low pH, thus acquiring caspase-like properties [27, 
29]. The catalytic dyad of legumain is shown to be His150 and Cys190 based on studies of 
mutant forms of the enzyme [30]. By investigating the catalytic dyad of legumain, it was 
proposed a similar folding of the catalytic site as the protease families of clostripains (family 
C11), caspases (family C14) and gingipain R (family C25), hence reflecting an evolutional 
relationship between these proteases [30]. In 2013 the first crystal structure of legumain was 
revealed and confirmed a 3D similarity (tertiary structure) to the caspases (Fig. 2A) [31, 32].  
Mammalian legumain is expressed as a proform of 56 kDa. The 56 kDa proform 
consists of a catalytic domain and a C-terminal prodomain composed of an activation peptide 
(AP, Lys287-Asn323) and a legumain stabilization and activity modulation domain (LSAM) 
[31]. The catalytic domain consists of six-stranded β-sheets flanked by five major α-helices 
(caspase-like fold; Fig. 2A) [31, 32]. The catalytic site is stabilized by the LSAM due to 
electrostatic interactions. The catalytic domain has a highly negatively charged surface while 
the LSAM has a positively charged surface explaining the stabilization of prolegumain at 
neutral pH. In the acidic environment of the lysosomes legumain is auto-processed to a 47 
kDa inactive and a 46 kDa active intermediate form [33]. Generation of the active 46 kDa 
form is thought to require cleavages of the proform at the C-terminal (Asn323) and at the N-
terminal (Asp25) sides (Fig. 2B) [33]. However, studies of the crystal structure revealed that 
only cleavage at Asn323 is required to achieve fully active legumain [31]. Although cleavage 
at Asn323, LSAM is believed to still be connected to the catalytic domain by electrostatic 
interactions at pH values above 4.5 [31]. Legumain can further be processed to an active 
mature form of 36 kDa, but this step is probably not autocatalytic and dependent on other 
proteases, e.g. the cathepsins (except cathepsin B) (Fig. 2B) [33, 34]. Recently, GAGs and 
alginates have been shown to accelerate auto-activation of prolegumain, possibly by 
electrostatic interference with the prodomain making the catalytic site more accessible [8, 35]. 
Also, legumain is postulated to have asparagine carboxyprotease activity [31].  
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Figure 2. The crystal structure (A) and the proposed multistep auto-activation process (B) of 
human legumain. A. Legumain contains three different domains; the legumain stabilization and 
activity modulation domain (LSAM, wheat), the activation peptide (Lys287-Asn323, blue) and the 
catalytic domain (green). To gain full legumain activity, cleavages at Lys-Arg-Lys289 (α-site; KRK289) 
and Asn-Asp324 (β-site; ND324) are required. The catalytic cysteine residue (C189) is sheltered by 
LSAM. Adopted from [31]. B. An illustration of the proposed process for auto-activation of 
legumain. The inactive 56 kDa proform is present in prelysosomal compartments and converted to 
the inactive 47 kDa and the active 46 kDa intermediate forms by sequential autocatalytic cleavage at 
Asn323 and Asp25 in an acidic enviroment. The autocatalytic cleavage at Asn323 is reversible. Cleavage 
at Lys289 is required to allow dissociation of the prodomain and revealing of the active site. The active 
46 kDa form is further trimmed to the mature active 36 kDa form. Adopted and modified from  [31, 
32]. 
 
Legumain is ubiquitously expressed in mammals with the highest expression in 
kidney, placenta, spleen, liver and testis [27, 36]. Although legumain is localized mainly to 
the lysosomes, translocation of legumain to other cell compartments (e.g. cell nuclei) and 
secretion to the tumor microenvironment have been reported [37-40]. Legumain have an Arg-
INTRODUCTION 
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Gly-Asp120 (RGD) motif which binds to the αvβ integrin receptor [37]. Upon binding to the 
αvβ integrin receptor, the pH optimum of legumain activity is increased, indicating that 
legumain also could be active in a slightly less acidic environment than the lysosomes [31].  
Legumain KO mice are born viable and fertile with no distinct anatomical or 
morphological abnormalities, however, decreased growth rate is observed [41]. In wild-type 
mice, legumain is expressed in the apical endocytic compartments of the proximal tubule cells 
which are critical for reabsorption and degradation of proteins [42]. Indeed, legumain KO 
mice have impaired kidney function, increased plasma creatinine concentrations and 
decreased glomerulus filtration rate (GFR) [43]. Also, the legumain-deficient mice have 
enlarged lysosomes and impaired processing of the two-chain active forms of cathepsin B, H 
and L [41]. Interestingly, fibronectin is accumulated in the tubulointerstitial area of legumain 
KO cells and direct cleavage of fibronectin by legumain is shown in vitro, indicating a role of 
legumain in extracellular matrix (ECM) turnover [44]. In addition, legumain can activate 
proMMP2 in vitro, also contributing in ECM degradation [45]. 
Legumain-deficient dendritic cells show impaired signaling of the Toll-like receptor 9 
(TLR9) due to reduced cleavage of the C-terminal segment of TLR9 [46]. Also, it seems that 
legumain has a role in processing of microbial tetanus toxin antigen for epitope presentation 
by MHC class II [47]. In addition, the initial step for removal of the invariant chain is 
performed by legumain and/or other proteases in B-lymphomas [48, 49]. However, in bone 
marrow-derived dendritic cells from legumain KO mice no difference was observed in MHC 
class II presentation compared to the wild-type littermates [50]. The C-terminal prodomain of 
legumain has been implicated as an inhibitor of osteoclast formation from macrophages, and 
thus bone resorption [51]. Legumain-deficient mice are characterized by significantly 
enhanced body temperature, progressive hepatosplenomegaly and cytopenia, which are 
symptoms of hemophagocytic syndrome/hemophagocytic lymphohistiocytosis [52]. 
Legumain is also suggested to have other functions such as annexin A2 cleavage [53], 
epidermal cornification of skin [54], degradation of SET in the granenzyme apoptotic 
pathway [55], proliferation of hepatocytes [56] and tau hyperphosphorylation in Alzheimer`s 
disease [57]. In atherosclerotic unstable plaques and tumors, legumain is over-expressed [37, 
58, 59]. 
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Cystatins 
 
Cystatins are endogenous inhibitors of the cysteine proteases. The cystatins were first 
discovered in chicken egg white in the late 1960s [60]. Since then, 12 human cystatins have 
been described and divided into type 1, 2 and 3 cystatins [10]. The general inhibition 
mechanism of all cystatins is reversible, substrate competition and equimolar. The cystatins 
generally bind their target enzyme tightly in the nanomolar to picomolar range [61]. The 
cystatins are classified to the clan IH, family I25, according MEROPS [2]. However, a sub-
classification of the three types is still used. The type 1 inhibitors, cystatin A and B (stefin A 
and B), are members of the subfamily I25A [2]. The cystatin A and B lack a signal peptide 
sequence and are without disulfide bonds and carbohydrate side-chains [62]. The type 2 
cystatins, including cystatin C, D, E/M, F, G, S, SA and SN (MEROPS subfamily I25B [2]), 
are slightly larger than the type 1 cystatins due to their signal peptide sequence [62]. Only the 
type 2 cystatins are able to inhibit legumain whereas all of the cystatin members are capable 
of inhibiting the cathepsins. The third type of cystatins is the kininogens, including high-
molecular-weight-kininogen and low-molecular-weight-kininogen, and are mainly found in 
the blood and synovial fluid [10, 63].  
The type 2 cystatins  
Legumain is inhibited by the endogenous type 2 cystatins; cystatin C (Ki=0.2 nM), E/M 
(Ki=0.0016 nM) and F (Ki=19 nM) [64]. The type 2 cystatins are small proteins with low 
molecular mass (approx. 15 kDa) and primarily secreted due to a secretory N-terminally 
signal-peptide sequence of approximately 27 amino acids. Cystatin C is the most thoroughly 
studied of the type 2 cystatins. The cathepsin-binding site of cystatins consist of a tripartite 
wedge-shaped structure complementary to the active site clefts of the cathepsins [65]. 
Surprisingly, the type 2 cystatins have an additional interacting site only for legumain, 
meaning that cystatin C is able to bind both cathepsin B and legumain at the same time in a 
1:1:1 complex [64].  
Cystatin C is found in all body fluids with the highest concentrations present in 
seminal plasma and cerebrospinal fluid [63]. Cystatin C can be used to measure GFR since 
the expression and secretion of cystatin C are relatively constant from most nucleated cells 
[66, 67]. It is believed that cystatin C is involved in pathological conditions such as 
rheumatoid arthritis, atherosclerosis, Alzheimer`s disease and cancers [68-71]. A mutation in 
the cystatin C gene (Leu68) has been linked to the dominantly inherited cystatin C amyloid 
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angiopathy (HCCAA) discovered in a population on Iceland [72, 73]. HCCAA is caused by 
amyloid deposition due to the nonfunctional Leu68 variant of cystatin C in the cerebral and 
spinal arteries and arterioles, leading to serious brain damage and recurrent hemorrhagic 
stroke [74].  
Cystatin E/M, the most potent inhibitor of legumain, have approximately 35 % amino 
acid sequence similarity to cystatin C. Cystatin E/M is expressed in a variety of human 
tissues, including heart, brain, placenta, lung, liver, pancreas, spleen, thymus, prostate, 
ovaries, small intestine and peripheral blood cells [75, 76]. In contrast to the other type 2 
cystatins, cystatin E/M has two forms; one glycosylated (17 kDa) and one unglycosylated (14 
kDa) [76]. The cystatin E/M gene (CST6) is located on chromosome 11, whereas the other 
type 2 cystatin genes are located on chromosome 20 [75, 76]. Cystatin E/M KO mice are 
associated with juvenile lethality and defective epidermal cornification, a disease recognized 
as human type 2 harlequin ichtyosis [77]. This defective cornification is due to involvement of 
uncontrolled legumain activity [54], and co-localization of cystatin E/M and legumain have 
been reported in hair follicles [78]. Cystatin E/M has often been described in relation to 
cancer as a potential tumor suppressor, and we and others have demonstrated that cystatin 
E/M inhibits invasion of human melanoma and oral carcinoma cells [76, 79, 80]. The 
expression of cystatin E/M is reduced in many cancer forms due to epigenetic silencing [81-
83]. On the other hand, over-expression of cystatin E/M is reported in pancreatic cancer [84]. 
However, it is generally accepted that increased cysteine protease activities and decreased 
expressions of the type 2 cystatins (C, E/M, and F) are associated with cancer, resulting in a 
potential disturbed protease/inhibitor ratio contributing to aberrant cellular functions.   
 
The role of cysteine proteases in diseases  
 
Cysteine proteases in cancer 
Cancer remains one of the leading causes of mortality in most developed countries with an 
estimated death rate of 7.6 million people each year [85]. Cancer is a complex multicausal 
disease which involves accumulation of genetic and/or epigenetic alterations in cells, resulting 
in expression of oncogenes and decreased expression of tumor suppressor genes. Both 
inherited and environmental factors are important in cancer development. The tumor cells 
abilities to form metastases and invade surrounding tissues characterize the malignant nature 
of cancer. The six characteristic hallmarks of malignant cancer are uncontrolled cell division, 
inflammations, alteration of the microenvironment, angiogenesis, invasion and metastasis 
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[86]. The matrix metallo- and serine proteases have been widely described in cancer 
progression. However, numerous studies also link cysteine proteases to the various aspects of 
cancer such as proliferation, invasion, apoptosis and metastasis [87]. In general, up-regulation 
of cysteine proteases can be associated with various aspects of cancer progression. Increased 
expression of cathepsin B, L and legumain are associated with a more aggressive tumor type 
and poor prognosis of breast, colon and ovary cancers, and in adenomas of the pituitary [59, 
88-91]. Also, the presence of cysteine protease inhibitors correlates with a more favorable 
prognosis of various cancer forms [92-95]. Cathepsins are suggested to interfere with 
apoptosis, proliferation, cancer growth, invasive growth and metastasis, thereby promoting 
malignancy [87]. Furthermore, there is diversity in the expression of specific cysteine 
proteases in tumor cells and tumor-associated cells at different stages during cancer 
development (Fig. 3A). This might indicate that each enzyme could have distinct functions in 
various cell types of the tumor, the tumor microenvironment and the surrounding tissues (Fig. 
3A) [87]. For example, legumain is found both in the malignant, endothelial and stromal cells 
as well as in tumor-associated macrophages (TAMs) [37, 96].  
Recently, TAMs were suggested to represent the 7th hallmark of cancer [97], reflecting the 
importance of TAMs in cancer development. TAMs consist of a polarized M2 (CD36+, 
CD68+, CD80-, CD163+) macrophage population, representing immunomodulatory and tissue 
remodeling macrophages. Many observations indicate that TAMs perform protumoral 
functions such as promoting tumor growth, angiogenesis, metastasis and suppression of 
adaptive immunity in the tumor environment [96, 98]. TAMs have direct interactions with the 
tumor cells both in the tumor microenvironment and of the perivascular macrophage-assisted 
tumor cell intravasation [99]. The protumoral cytokines secreted by TAMs include 
interleukins (ILs) such as IL-10, transforming growth factor-β (TGF-β), vascular endothelial 
growth factor (VEGF), tumor necrosis factor alpha (TNFα) and MMPs [100, 101]. The 
presence of extensive TAMs infiltration is correlated with poor prognosis [102, 103]. In 
recent studies, anti-TAMs effects are shown to contribute to tumor suppression. For example, 
the antineoplastic agent trabectedin has a selective cytotoxic effect on TAMs, resulting in 
significantly reduced production of IL-6, monocyte chemotactic protein-1 (MCP-1) and tumor 
growth [104]. Interestingly, abundant expression of legumain is present in TAMs [38, 96].  
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Figure 3: Potential roles of cysteine proteases in tumor and tumor-associated cells. A. The 
diversity of cysteine protease expressions in tumor and tumor-associated cells are shown. Cat, 
cathepsin. Modified from [87]. B. Suggested extra- and intracellular functions of cysteine proteases 
in cancer progression. Modified from [105]. 
As mentioned, cysteine proteases are suggested to participate in cancer progression (Fig. 
3B). The mechanisms behind the up-regulation of cysteine proteases in cancer are believed to 
be gene amplification, increased transcript variants, increased post-transcriptional stability 
and/or epigenetic methylation [87]. The cysteine cathepsins and legumain are mainly 
localized to lysosomes, however, in cancer the subcellular localization of cathepsins and/or 
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legumain are changed [106-108]. For example, legumain is secreted to the tumor 
microenvironment and is associated with the plasma membrane [106, 107]. Also, cathepsin B, 
L and legumain are reported to be present in the nucleus of cancer cells and suggested to 
participate in histone degradation [40, 109, 110]. Both direct and indirect degradation of ECM 
and cell adhesion proteins are extracellular effects of cysteine proteases in cancer progression 
[87, 105]. The suggested ECM protein substrates of cysteine proteases are laminin [111, 112], 
type IV collagen [111], tenascin C [113] and fibronectin [44]. Furthermore, the cysteine 
proteases can participate in proteolytic cascade activation [105]. Particularly, cathepsin B has 
been shown to activate pro-urokinase-type plasminogen activator (pro-uPA) and uPA is 
important in degradation of the tumor matrix and basal membranes, resulting in increased 
tumor progression by migration and invasion [114, 115]. Also, degradation of cell-adhesion 
proteins such as E-cadherin by cathepsins B, L and S is described, leading to increased 
disseminative ability of tumor cells [116]. In addition, intracellular participation of cysteine 
proteases in ECM degradation has been addressed. For example, intracellular degradation of 
collagen in the tumor, macrophages and fibroblasts by cathepsins has been observed [117-
119], in agreement with the finding of the endocytic transmembrane glycoprotein uPA 
receptor-associated proteins which direct the collagen IV for lysosomal delivery and 
degradation [87].    
Cysteine cathepsins are involved in intracellular functions such as apoptosis [120], a key 
process in cancer development and progression. Both cathepsins and calpains have recently 
been shown to trigger apoptosis by different pathways [120]. It is believed that increased 
permeabilization of the lysosomes result in translocation of cathepsins to the cytosol, resulting 
in cleavage of substrates involved in apoptosis. The induction of leaky lysosomes is probably 
both stimulus- and cell type-dependent. For example, generation of reactive oxidative species 
(ROS) causes lysosomal leakage by destabilizing the lysosomal membrane [120-122]. In cell 
free systems, cathepsin B-release from the lysosomes have been shown to be mediated by 
caspase-2 or -8. Release of cathepsins into the cytosol during apoptosis is involved in 
degradation of the antiapoptotic Bcl-2 family members, including the proteolytic activation of 
Bid and/or activation of caspases [123-125]. In hepatocytes, cathepsin B has shown to 
contribute to apoptosis by a caspase-8-dependent process [120, 126]. In addition, TNFα has 
shown to increase cytosolic cathepsin B and subsequently enhanced mitochondrial release of 
cytochrome C [127] and cathepsin B KO mice were more resistant to TNFα-induced 
apoptosis compared with their wild-type littermates [128]. Furthermore, cathepsin B has in 
cell free samples been reported to cause chromatin condensation, a morphological hallmark of 
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apoptosis [120]. There are also examples of direct processing of caspases by cathepsins. For 
example, cathepsin B is able to activate caspase-11 [129], whereas cathepsin L is able to 
activate caspase-3 in vitro [130]. Interestingly, a pro-survival role of legumain has been 
reported in the parasite Blastocystis [131]. Also, legumain has been shown to cleave and 
inactivate SET, an inhibitor of the DNAse NM23-H1 [55], leading to DNA cleavage and 
apoptosis. This novel pathway of apoptosis (granzyme pathway) is initiated by the cytotoxic T 
cells, and is including delivery of granules containing granzyme A and B to the target cells via 
perforins [132, 133].   
Cysteine proteases in atherosclerosis 
Atherosclerosis is a chronic inflammatory disease and a major cause of morbidity and 
mortality in industrialized countries. It is a complex disease characterized by atherosclerotic 
lesions containing excessive inflammation and lipid accumulation [134]. Typical findings are 
increased thickness of the artery wall, foam cell formation and hardening of the arteries. The 
atherosclerotic lesions are divided into stable and unstable plaques. The unstable plaques 
account for only 10-20 % of all lesions, but are responsible for 80-90 % of all acute clinical 
events [135]. In general, stable plaques tend to be asymptomatic and are usually rich in ECM 
and smooth muscle cells, whereas unstable plaque are rich in macrophages and macrophage-
derived foam cells and only the fibrous cap separates the lesion from the arterial lumen [136]. 
The fibrous cap is vulnerable to rupture, which can result in formation of thrombus and 
eventually occlusion and/or thromboembolism. The pathology of atherosclerosis involves 
many different cells such as macrophages, T lymphocytes, endothelial cells, vascular smooth 
muscle cells (VSMC) as well as platelets [100, 137].  
Macrophages are as mentioned important cells in regulation and development of 
atherosclerosis [100]. Monocytes from blood enter the intima through interaction with up-
regulated adhesion molecules on the inflamed and activated endothelium, and differentiate to 
macrophages. Macrophages engulf modified lipoproteins and transform into foam cells 
constituting fatty streaks and later the fatty core of an atherosclerotic plaque. In addition to 
lipid accumulation, macrophages are inflammatory cells releasing a variety of inflammatory 
cytokines such as TNFα, IL-1 and CXCL8, linking the two hallmarks of atherosclerosis: 
lipids and inflammation [100]. The interaction between lipids and macrophages are mediated 
through scavenger receptors such as scavenger receptor A (SR-A), CD36 and lectin-like 
oxidized LDL receptor-1 (LOX-1), which all promote uptake and accumulation of lipids.  
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Differentiated macrophages have distinct characteristics. The M1 macrophages 
(CD36-, CD68+, CD80+, CD163-) produce inflammatory cytokines and act as cell killing 
effectors, whereas the M2 macrophages (CD36+, CD68+, CD80-, CD163+) moderate the 
inflammatory response and remove debris [138, 139]. In addition, M2 macrophages promotes 
angiogenesis and tissue remodeling due to release of the anti-inflammatory IL-10 and TGF-β 
[100]. Within the atherosclerotic plaque, increased levels of M1 macrophages are associated 
with accelerated atherogenesis and increasingly unstable lesions due to secretion of MCP-1, 
MMPs and stromelysin [138, 140]. In addition, macrophages also secrete active cathepsin B, 
L and S which directly or indirectly digest and weaken the fibrous cap and contribute to 
plaque instability [141]. Interestingly, increased mRNA-expression of MMP-9, cathepsin B 
and legumain has been observed in unstable plaques compared to stable plaques [58], 
suggesting a direct or indirect role of legumain in ECM degradation of the fibrous cap either 
by activating MMP-2 [45] or by direct cleavage of fibronectin [44]. The main contributor for 
increased legumain expression in plaques is probably the macrophages, since increased 
legumain was abundant co-localized with the macrophage marker CD68 within the unstable 
plaques [58]. 
 
Pharmacological interventions  
 
Statins 
Statins are cholesterol-lowering drugs prescribed worldwide to patients with 
hypercholesterolemia. Statins interfere with the de novo synthesis of cholesterol, resulting in 
decreased blood LDL-cholesterol and prevention of cardiovascular morbidity and mortality 
[142-144]. There are six statins marketed in Norway today; simvastatin, lovastatin, 
pravastatin, fluvastatin, atorvastatin and rosuvastatin. All these statins inhibit the rate-limiting 
enzyme HMG-CoA reductase in the cholesterol biosynthesis (Fig. 4) but have different 
lipophilicity, half-life and potency [145]. The statins are administered either as an inactive 
lactone form (simvastatin and lovastatin) or as an active acid form (atorvastatin, fluvastatin, 
rosuvastatin and pravastatin). There is equilibrium between the lactone and acid forms in vivo 
controlled by hydrolysis, β-oxidation and glucuronidation [146, 147]. Although statins down-
regulate the cholesterol synthesis, the main effect on cholesterol is caused by a subsequent up-
regulation of the LDLR gene [148]. Inhibition of HMG-CoA reductase by statins also prevents 
synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway 
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such as farnesyl pyrophosphate (farnesyl-PP) and geranylgeranyl pyrophosphate 
(feranylgeranyl-PP) (Fig. 4) [149]. These intermediates are functioning as lipid attachments 
for posttranslational modifications of a variety of proteins including small GTPases such as 
Ras, Rho, Rac and Rab [149, 150]. Thus, isoprenylations of proteins regulates the covalent 
attachment, subcellular localization and intracellular trafficking of proteins.  
In clinical trials, the overall effects of statins in prevention of coronary heart disease 
appear to be greater than what might be expected from changes in the lipid levels, suggesting 
effects beyond the cholesterol-lowering [143, 144]. These so-called pleiotropic effects of 
statins are suggested to include effects on monocytes/macrophages, endothelial, vascular 
smooth muscular and stem cells.  
Although statins are generally well-tolerated, side effects like myotoxicity have been 
reported; fatigue, myalgia, myositis and life-threatening rhabdomyolysis [151, 152]. All these 
conditions fall under the myotoxicity term and unfortunately all statins are associated with 
myotoxicity. The incidence of statin-induced myotoxicity in patient is approximately 1-5 % 
based on data from randomized clinical studies [153]. However, in observational studies as 
many as 9-20 % of the patients experienced some kind of muscle related side effects [154, 
155]. Simvastatin has the highest incidence rate of rhabdomyolysis defined as creatine kinase 
(CK) levels greater than 10 times the upper normal limit [153]. However, patients still 
experience myotoxicity with no or slightly increased CK. The toxicity of statins is dose-
dependent, and the inactive lactone forms are reported to be more toxic than the active acid 
form [156]. Acute application of statins to human muscle cells in vitro have been shown to 
trigger apoptosis, and it is suggested that this effect is mediated by activation of 
phospholipase C (PLC)-γ1 and  phosphatidylinositol (PI-3 kinase) [157, 158]. Interestingly, 
this apoptotic process was prevented by adding mevalonate, but not when squalene epoxidase 
or the squalene synthase were inhibited [159]. This indicates that inhibition of isoprenoid 
compounds such as farnesyl-PP, geranylgeranyl-PP, ubiquinone and/or dolichol were 
responsible for apoptosis [160, 161]. Furthermore, activation of the cysteine proteases, 
calpains, caspase-3 and -9 were observed in cell death caused by statins [162]. Interestingly, 
combining treatment of statins with bicarbonate used to control intracellular pH, reduces the 
risk of apoptosis and consequently myotoxicity [163], suggesting that lysosomal enzymes in 
the acidic cellular compartments could be important in statin-induced myotoxicity. 
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Figure 4: The cholesterol biosynthesis pathway. Statins block the rate-limiting step in the 
cholesterol synthesis by inhibiting the enzyme HMG-CoA reductase. Reduced activity of HMG-CoA 
reductase leads to decreased levels of downstream products such as cholesterol, dolichols, 
ubiquinone, and Ras-, Rho-, Rac-, Rab GTPase.  
 
Drugs utilizing cysteine proteases 
Pharmacological targeting of cysteine proteases such as the cathepsins and legumain could be 
beneficial since these are up-regulated in cancer and atherosclerosis. In general, inhibition of 
proteases has been a successful strategy in therapeutic interventions, including drugs 
inhibiting the angiotensin-converting enzyme and the human immunodeficiency virus 
protease. However, knowledge about functions, substrates, localizations and regulations of the 
cysteine proteases is insufficient to be able to anticipate the outcome of inhibiting one 
individual cysteine protease [14]. Potential problems with redundancy could also occur since 
target substrates could be cleaved by several enzymes not inhibited. Also, targeting the 
ubiquitously expressed enzymes such as cathepsin B and L could potentially be more 
hazardous compared to targeting enzyme with more specific and restricted expression such as 
cathepsin K and S. For example, inhibition of cathepsin K activity seems promising for the 
prevention of osteoporosis because of the prominent role of cathepsin K in osteoclasts and 
INTRODUCTION 
17 
bone remodeling [164, 165]. Indeed, odanacatib is a drug candidate for being the first 
cathepsin K inhibitor for prophylaxis of osteoporosis [166], and phase III clinical trials are 
currently ongoing. Also, targeting cathepsin S mainly localized in B-lymphocytes, 
macrophages and dendritic cells could be beneficial in halting development of autoimmune 
diseases such as myasthenia gravis and Sjögrens syndrome [167-169]. 
An alternative approach in drug development is to exploit the specific substrate cleavage 
site of an enzyme by conjugating a peptide sequence mimicking the substrate peptide 
cleavage site to a toxic compound or to an antibody which upon cleavage releases the toxic 
compound or exposes the antigen-binding site of the antibody [170-172]. Recently, the Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) accepted the 
use of brentuximab vedotin in relapsed or refractory Hodgkin’s lymphoma (HL) and relapsed 
or refractory systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin is an 
antibody-drug conjugate targeting the cell-membrane protein CD30 [172], which is over-
expressed in HL and sALCL. The antibody-drug conjugate contains a monoclonal antibody 
(anti-CD30), a stable linker and the cytotoxic agent auristatin [172]. The linker has a 
cathepsin-cleavable peptide that upon cleavage releases auristatin. This approach seems 
promising, shown in clinical trials that 34 % of patients with refractory HL achieved complete 
remission and increased survival after treatment with brentuximab vedotin [173]. In patients 
with sALCL, 57 % of the patients achieved a complete remission and 29 % achieved partial 
remission [174]. 
A similar strategy is to synthesize and target a prodrug or probody to a protease with 
highly restricted cleavage and expression pattern such as legumain. Recently, the probody 
IHZTM was developed containing a masking peptide blocking the antibody`s antigen-binding 
site (e.g. to the epidermal growth factor receptor). The masking peptide was connected to the 
antibody through a protease substrate-containing linker cleavable by uPA, matriptase, and 
legumain [170]. Target-mediated toxicity constitutes a major limitation for the development 
of therapeutic antibodies. Therefore, improved safety profile is provided with a probody in 
cancer. So far no clinical trials have been initiated but convincing results have also been 
reported for similar approaches in the construction of legumain-cleavable prodrugs based on a 
legumain-cleavable peptide linked to the cytotoxic drugs doxorubicin, etoposide and auristatin 
[37, 39, 175, 176]. In these studies cell specific targeting of the prodrugs and toxicity in 
legumain over-expression cells have been demonstrated both in vitro and in vivo. Recently, 
selective targeting of TAMs by legumain-activating prodrugs represents a novel anticancer 
strategy [177].  
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Furthermore, a DNA vaccine has been developed based on targeting legumain in TAMs 
[96]. The vector construct was based on the pCMV/myc/cyto vector backbone, and was 
incorporated with the LGMN gene fused to the C-terminus of a mutant polyubiquitin, which 
makes the antigen processing by the proteasome more efficient [178]. Mice injected with the 
legumain-based DNA vaccine one week prior to the injection of 2 x 105 D121 non-small lung 
tumor cells significantly survived longer, had reduced number of TAMs and metastasis 
compared to control [96]. 
 
Colchicine 
Colchicine is an anti-inflammatory drug approved as monotherapy to treat inflammatory 
diseases such as gout and Mediterranean fever, and the use in Norway have increased by 3-
fold during the last decade [179]. Recently, a clinical trial showed that low-dose use of 
colchicine (0.5 mg/day) had promising results also in prevention of cardiovascular disease in 
patients [180]. Colchicine inhibits microtubule polymerization by effectively binding to the 
colchicine binding site (CSB) in tubulin. CSB is one of the most important pockets for 
potential polymerization destabilizers such as podophyllotoxin and nocodazole [181]. 
Colchicine is under investigation as an anticancer drug. However, the therapeutic value of 
colchicine against cancer is restrained by its low therapeutic index due to its lipophilic nature. 
Therefore, colchicine can be exploited in a prodrug strategy, due to its cytotoxicity and 
lipophilic properties. 
AIMS OF THE PRESENT STUDIES 
19 
AIMS OF THE PRESENT STUDIES 
 
The overall aim of this thesis is to expand our knowledge about the regulation of the cysteine 
protease legumain in human cell model systems, and exploit legumain in pharmacological 
interventions. 
 
Specific aims are as follows:  
x To investigate the expression, processing, activity, sub-cellular localization and 
secretion of legumain, as well as the interplay with cystatin E/M. 
x To investigate effects of statins (atorvastatin and simvastatin) on the activity, 
expression and localization of legumain in macrophages and skeletal myotubes. 
x To study the cytotoxic effects of a new legumain-cleavable colchicine prodrug in cells 
with various expression levels of active legumain. 
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SUMMARY OF PAPERS 
 
Paper I  
 
Transfected monoclonal cell lines of human embryonic kidney cells (HEK293 cells), over-
expressing legumain, cystatin E/M, or both, were established and studied. The cell lines were 
used to investigate the regulation, localization and interplay between legumain and its most 
potent inhibitor, cystatin E/M. Although legumain is mainly a lysosomal enzyme and the 
inhibitor is a secretory protein, most interestingly the study showed that both legumain and 
cystatin E/M are able to be secreted in the cell medium as well as being internalized by cells. 
Surprisingly, cystatin E/M was present in the nucleus of cystatin E/M over-expressing 
HEK293 cells. These observations could explain how cystatin E/M can perform regulatory 
functions towards legumain both inside and outside the cell.  
 
Paper II  
 
Macrophages play a pivotal role in development of atherosclerosis and express lysosomal 
cysteine proteases such as legumain. Statins, HMG-CoA reductase inhibitors, are prescribed 
worldwide to patients with hypercholesterolemia. Previously, atorvastatin has been shown to 
down-regulate legumain mRNA in monocytes isolated from patients. In this study, the 
expression, activity and secretion of legumain was studied in established cellular models of 
monocytes/macrophages. Legumain levels were highly increased during monocyte-to-
macrophage differentiation. Interestingly, most of the legumain produced in primary 
monocyte-derived macrophages was found to be secreted. Secretion of legumain from 
macrophages could explain the surprising observation of legumain present in human sera. 
Finally, atorvastatin treatment reduced both legumain processing, activity and secretion in 
macrophages (PM-derived and RAW264.7 macrophages), which could be important in 
understanding the pleiotropic effects of statins. 
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Paper III 
 
Statins, HMG-CoA reductase inhibitors, are generally well-tolerated. However, side effects 
like myotoxicity occur. The mechanisms for statin-induced myotoxicity are still poorly 
understood. In this study, the effects of simvastatin were studied on glucose metabolism and 
legumain levels in human primary myotubes. A dose-dependent decrease in both glucose 
uptake and oxidation were observed in mature myotubes after exposure to simvastatin in 
concentrations not influencing cell viability. In addition, simvastatin caused a decrease in 
maturation and activity of legumain. Dysregulation of glucose metabolism and decreased 
legumain activity by simvastatin points out new knowledge about statins effects on skeletal 
muscle, and may contribute to the understanding of the myotoxicity observed by statins. 
 
Paper IV 
  
The cysteine protease legumain have remarkably restricted substrate specificity and is the 
only known asparaginyl endoprotease. Over-expression of legumain is reported in malignant 
cancers and unstable atherosclerotic plaques, and utilization of legumain is a promising 
approach to activate prodrugs, and thus targeting drugs. In this study we synthesized a 
prodrug by conjugating the legumain-cleavable peptide Suc-Ala-Ala-Asn-Val to the cytotoxic 
colchicine which upon cleavage by legumain released valyl colchicine.  
The prodrug was shown to be more cytotoxic to cells expressing active legumain 
(HCT116 and M38L cells) than control cells (SW620, HEK293 and M4C cells). This 
indicates a relationship between toxicity of the prodrug, activity of legumain and release of 
valyl colchicine in the cells. Furthermore, co-administration of the prodrug with either 
cystatin E/M or the endocytosis inhibitor Dyngo-4a inhibited cell death, indicating that the 
prodrug toxicity was dependent on both asparaginyl endoprotease activity and endocytosis. 
This colchicine prodrug adds to a legumain-cleavable prodrug strategy approach and could 
possibly be of use both in targeted anti-cancer and anti-inflammatory therapy. 
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GENERAL DISCUSSION 
 
Methodological considerations  
 
Specificity of antibodies 
In present work legumain, cystatin E/M, cathepsin B and L antibodies were used. Antibodies 
are routinely used in bioscience techniques such as immunoblotting, enzyme-linked 
immunosorbent assays (ELISA), immunofluorescence, immunohistochemistry (IHC), 
immunoprecipitation (IP) and flow cytometry. There are over 180 suppliers of antibodies 
worldwide offering approximately 350,000 antibodies for research purpose [182]. However, 
no universal standards of validation of the quality of antibodies are adapted. This causes 
concerns since vendors provide different levels of validation which is probably dependent on 
the company`s balance between making a profit and providing high quality. It is generally 
accepted that the responsibility to ensure proof of antibody specificity is on the 
purchaser/publisher and not the vendors concerning publishing. It is essential to ensure that 
the purchased antibody is specific, selective and reproducible for the appropriate applications 
to obtain reliable results. 
The specificity of an antibody depends on many factors such as the type and number of 
immunogens as well as the antibody production method. The antibody selectivity is further 
complicated by the choice between monoclonal (mAbs) or polyclonal (pAbs) antibodies. The 
generation of mAbs and pAbs is quite different. The production of mAbs is based on single 
clones of hybridomas producing antibodies with high purity against a single epitope with one 
specific affinity. The advantages of using mAbs are that they show a high degree of 
specificity, but usually work in just a limited set of conditions. Polyclonal antibodies are 
typically produced in a suitable mammal such as rabbit or goat. An antigen is injected into the 
animal and the B-cells will usually produce various immunoglobulins specific for the antigen, 
resulting in a pool of antibodies with various affinities for the antigen. On the other hand, the 
advantage of pAbs is that it could be used in many different methods, but could be unselective 
due to several affinities towards many epitopes.  
The specificity of an antibody is further determined by the type of immunogens used. The 
immunogens can either be a synthetic peptide or purified proteins. The advantage of synthetic 
peptides as immunogens is that the amino acid sequence to which the antibody binds is 
known. However, antibodies generated by synthetic peptides may not work well against 
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native proteins with intact conformation with or without post-translational modifications 
[183]. For example, synthetic antibodies may not be suitable for immunofluorescence, IP and 
IHC experiments, but could be used in analysis studying denatured proteins e.g. sodium 
dodecyl sulfate (SDS) immunoblotting. On the other hand, antibodies generated against 
purified proteins works well for proteins in their native conformation in analysis such as IP 
and IHC, but perhaps not for SDS immunoblotting and vice versa. The complexity of the 
specificity of an antibody is further complicated during fixation methods as used in e.g. 
immunofluorescence. The fixation process could alter the native form of a protein, thereby 
exposing epitopes that are not apparent in the native form and vice versa. For example, an 
antibody could recognize one epitope in fresh tissue, but unable to recognize the same epitope 
in a fixed tissue [184].  
For the studies of human legumain and cystatin E/M in this thesis, well-characterized 
pAbs were used [40, 80, 175, 185]. The legumain (R&D systems, AF2199) and cystatin E/M 
(R&D systems, AF1286) pAbs were used in confocal imaging (immunofluorescence) of fixed 
samples and immunoblotting. Application of the pAbs in these techniques has previously been 
described [40, 80, 82]. The immunogens for producing these pAbs was proteins of legumain 
(amino acids 18-433) and cystatin E/M (amino acids 29-149), respectively. Polyclonal 
antibodies usually detect various forms of its target protein. For cystatin E/M both the 
glycosylated and unglycosylated forms are detected, and for legumain the proform, 
intermediate forms and active forms are detected. In the legumain ELISA experiments we 
used a kit (R&D Systems, BAF2199) containing a mAb for capturing and a biotinylated pAb 
(as described above) for detection. Well-characterized cathepsin B (Calbiochem, 219408) and 
L (R&D systems, AF952)) pAbs were also used in this work. 
The legumain pAb showed specificity to legumain since introducing siRNA targeting 
legumain mRNA in cells markedly decreased the detection of legumain in cell lysates using 
pAbs [40]. Also, increased detection of legumain and cystatin E/M were observed in legumain 
and cystatin E/M over-expressing cells by the legumain and cystatin E/M pAbs, respectively 
(paper I). A murine monoclonal antibody against cystatin E/M (Santa Cruz, mouse, sc-
73881) was used in confocal imaging (paper I) to avoid cross reactivity in overlay 
experiments against legumain and cystatin E/M pAbs originating from goat. The use of a 
lysotracker would have been useful but was difficult since the integrity of the lysosomes was 
affected by the fixation process. Therefore, acyl sulphatase B (a soluble lysosomal protein) 
mAb was used as a lysosomal marker in paper III.    
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Specificities of substrates  
The legumain activity in this work was measured by recording the cleavage of the peptide 
substrate Z-Ala-Ala-Asn-AMC (Z-AAN-AMC, Table 1). Validation of the peptide cleavage 
in crude samples such as tissue homogenates and cell lysate samples is described elsewhere 
[27, 186]. Since legumain is the only well-characterized asparaginyl endoprotease, Z-Ala-Ala-
Asn-AMC is thought to be suitable for detection of legumain activity. Also, the use of an 
acidic assay buffer (pH 5.8) favors the activity of cysteine proteases. The pH optimum for 
legumain activity is 6.4, but due to stability issues, a pH value of 5.8 is selected in this 
analysis [27]. The specificity of the substrate (Z-Ala-Ala-Asn-AMC) has been tested in 
combination with a broad cysteine cathepsin inhibitor (E-64). However, no change in 
cleavage of Z-Ala-Ala-Asn-AMC was observed by introducing E-64, excluding substrate 
cleavage by cysteine cathepsins [186]. Also, the addition of egg-white cystatin to the samples 
caused a complete inhibition of substrate cleavage, indicating legumain substrate specificity. 
Surprisingly, the cleavage of Z-Ala-Ala-Asn-AMC in THP-1 macrophages was partly 
inhibited by both E-64 and cystatin E/M, thus indicating the presence of an additional 
protease with AEP-activity in these cells (paper II). In paper I, we showed a correlation 
between the activity and expression of the mature form of legumain. By co-over-express 
legumain and cystatin E/M in M3CL cells, reduced legumain activity was observed compared 
to the legumain over-expressing M38L cells, indicating that the method used for legumain 
activity was satisfactory. Linearity of the assay was established by measuring the initial 
substrate cleavage rate when limiting the substrate consumption to less than 2 %. Values of 
Kcat and Km for Z-Ala-Ala-Asn-AMC were 46 s-1 and 50 μM, respectively, indicating that this 
substrate is suitable for measuring enzyme kinetics. The ratio Kcat/KM for legumain cleaving 
Z-Ala-Ala-Asn-AMC was estimated to be approximately 9.2*105 M-1 S-1 (Table 1) [27]. 
Cathepsin B activity was measured in a similar way but using another peptide 
substrate (Z-Arg-Arg-AMC) as described in the literature [187, 188]. Z-Arg-Arg-AMC (Z-
RR-AMC, Table 1) exhibits very good specificity to cathepsin B due to an Arg residue in the 
P2 position (Table 1). However, it should be noted that the Kcat/Km ratio of cathepsin B is 
higher for the substrate Z-Phe-Arg-AMC than for Z-Arg-Arg-AMC. However, Z-Phe-Arg-
AMC is a relative unselective substrate which can be cleaved by most papain-like cysteine 
endoproteases. The pH range for maximum activity of the cysteine cathepsins are between 
7.5-8 [189], but due to stability issues the activity measurements are normally carried out at 
lower pH values (5.1-6.5; Table 1). Furthermore, dithiothreitol (DTT) should always be 
included in the assay due to oxidation of the active site of cysteine proteases. 
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Cathepsin L activity was measured by cleavage of the peptide substrate Z-Phe-Arg-
AMC (Z-FR-AMC, Table 1) and the catalytic efficacy is good (Table1). Since this peptide 
also is cleaved by cathepsin B (see above), a negative control including a selective cathepsin 
B inhibitor (CA-074) was included [188].  
 
Table 1. Substrate specificities and enzyme kinetic parameters of legumain and cysteine 
cathepsins.  
 
Cell lines and primary cell cultures  
In the work presented in this thesis, in vitro cell models of various origins have been used, i.e. 
commercially available cell lines (HEK293, RAW264.7, HCT116, SW620 and THP-1 cells) 
as well as primary cell cultures isolated from human biopsies (skeletal muscle cells) and 
whole blood (monocytes). Advantages of using cell lines instead of cells from primary 
cultures are that the cells are more easily controlled in vitro which make experiments easier 
and more reproducible. However, cells from cell lines are often dissimilar in behavior and 
response compared to cells in vivo, which makes them difficult to compare. Also, the cell 
lines used in our studies are immortalized cells of cancer origins except the RAW264.7 
macrophages which were immortalized by transfection of a leukemia virus. Cell lines in vitro 
are able to live without the influence of physiological factors such as neuronal input, exposure 
of endocrine and serum components, and interplay of other cells. Although effects observed in 
cell lines are difficult to extrapolate to normal cells and tissues in vivo, in vitro cell models are 
valuable in basic research. 
In this study, native HEK293 cells were transiently and stably transfected using a 
mixture of liposomes (Lipofectamine 2000) and either a LGMN pcDNA3.1 plasmid and/or a 
Substrate Enzyme Km 
(μM) 
Kcat 
(S-1) 
Kcat/Km 
(M-1 S-1) 
Conditions used: Ref. 
Buffer pH Temp. (°C) 
Z-AAN-AMC Legumain 50 46 9.2 * 105 40 mM citric acid 
121mM Na2HPO4 
5.8 30 [27] 
Z-RR-AMC Cat B 390 1340 3.4 * 106 88 mM KH2PO4, 
12 mM NA2HPO 
6.0 40 [190] 
Cat V 168 0.011 6.5* 101 50 mM KH2PO4 6.5 37 [191] 
Cat K 23 0.0005 2.2* 101 100 mM KH2PO4 6.5 37 [192] 
Cat S 220 0.02 9.1* 101 50 mM NaOAc 5.5 25 [193] 
Z-FR-AMC Cat B 
 
150 1500 9.9 * 106 88 mM KH2PO4, 
12 mM NA2HPO 
6.0 40 [190] 
Cat L   5.1* 106 100 mM NaOAc 5.5 37 [192] 
Cat S 20.8 2 96 90 mM NaPO4 6.5 25 [194] 
Cat K 7.5 0.9 1.2* 105 100 mM KH2PO4 6.5 37 [192] 
Cat V 6.4 0.71 1.1* 105 50 mM KH2PO4 6.5 37 [191] 
Cat S 22 1,9 8.6* 103 50 mM NaOAc 5.5 25 [193] 
Cat F 0.44 2.5 5.7* 106 50 mM KH2PO4 6.5 25 [195] 
Cat X 63 0.22 3.5* 103 20 mM NaOAc 5.1 37 [196] 
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CST6 pTracer plasmid. The HEK293 cells were used since the endogenous expressions of 
legumain and cystatin E/M in these cells are low, and the cells are easily transfected and 
cultured. The pcDNA3.1 plasmid contains a selective antibiotic resistance gene 
(aminoglycoside 3`-phosphotransferane, APT3`II) which upon expression makes the cells 
resistant to the antibiotic G418. Also, a selective antibiotic resistance gene (Streptoalloteichus 
hindustanus ble gene) was incorporated in the pTracer plasmid which upon expression makes 
the cells resistance to zeocin. Stably transfected monoclonal cell lines were obtained by 
culturing the transfected cells in the presence of either G418 and/or zeocin for the legumain 
(M38L), cystatin E/M over-expressing HEK293 (M4C) and double-transfected (M3CL) cells, 
respectively. Single cell colonies (clones) were selected and the clones with the highest 
protein expression of legumain (M38L) and/or cystatin E/M (M4C, M3CL) were used, 
respectively. Control cell clones transfected with the empty vectors did not show any 
difference in legumain or cystatin E/M levels compared to untransfected HEK293 cells. 
Therefore, native HEK293 cells were used as control cells.  
The stably transfected monoclonal cell line models were mainly used in paper I and 
IV. Visually, the M38L cells seemed to have a faster and the M4C cells to have a slower 
growth rate than the native HEK293 cells. These observations were verified in a proliferation 
assay using the INCUCYTE™ Kinetic Imaging System. The proliferation rate of M38L cells 
were shown to be significantly increased compared to native HEK293 cells (Fig. 5). On the 
contrary, M4C cells had a significantly decreased proliferation rate compared to M38L and 
native HEK293 cells. These findings suggest a role of legumain and cystatin E/M in 
regulation of cell proliferation. Interestingly, a pro-survival role of legumain has been 
reported in the parasite Blastocystis [131]. Legumain has been shown to inactivate SET, an 
inhibitor of the DNAse NM23-H1 [55], and regulate the proliferation of hepatocytes [56]. 
Also, legumain has been shown to cleave histone 3.1 in vitro, suggesting a role in the DNA 
replication [40].  
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Figure 5. Proliferation of legumain over-expressing (M38L), cystatin E/M over-expressing 
(M4C) and native HEK293 cells. Native HEK293, M38L and M4C cells (50,000 cells/well) were 
cultured in 6-well plates, and the proliferation rate was measured every second hour in the 
INCUCYTE™ Kinetic Imaging System (*p<0.05, linear regression, n=4).  
 
In paper II, monocytes/macrophages were the main focus. Primary human monocytes were 
isolated from healthy individuals by collecting fresh full blood using Vacutainer vials with 
sodium heparin caps. The blood was centrifuged and the leucocytes were collected. The 
leucocytes were then cultured, and the monocytes were separated by adherence to the plastic 
well bottom. Monocytes-to-macrophages differentiation of primary monocytes was performed 
by stimulation with 100 ng/ml macrophage colony-stimulating factor (M-CSF), whereas the 
monocytes-to-macrophages differentiation of THP-1 cells was performed by incubation with 
40 ng/ml PMA or 5 ng/ml TNFα.  
The human primary skeletal muscle cells were derived from biopsies from healthy kidney 
donors at the Oslo University Hospital, and satellite cells were isolated (paper III). The 
model of in vitro culturing of myotubes is well-established in the laboratory, based on the 
method of Henry et al. 1995 and modified by Gaster et al. [197, 198]. The satellite cells are 
activated to proliferate and differentiate into polynuclear myotubes in vitro by introducing 
myogenic growth conditions such as the serum substitute Ultroser G, low concentration of 
serum (2 % FCS) and adherence to ECM. This model represents the best available in vitro 
model system for human skeletal muscle fibers (myotubes) [199]. One advantage of primary 
cells is that some of the innate characteristics of the donor are preserved [199]. However, 
work with primary cells can also be demanding, because primary cells have a limited lifespan 
(days) and are often subjected to infections because of the isolation process. Also, the purity 
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of the isolated primary satellite cells can be questionable due to frequently contamination of 
fibroblasts.  
 
Subcellular localization of legumain and cystatin E/M 
 
Legumain is suggested to have a range of cellular functions in various subcellular 
compartments. To proteolytically cleave its substrates, legumain must be activated at the site 
of substrate interaction or transported to the site in its active form. Both maturation and 
stability of legumain and the presence of endogenous cystatin inhibitors are factors that 
regulate proteolytic activity. In addition, environmental conditions and subcellular 
localizations are other factors that regulate the final activity of legumain. Therefore, any 
knowledge about the subcellular localizations and interplay of legumain and its endogenous 
inhibitors could potentially explain the role of legumain in different physiological or 
pathological settings, and could be exploited in therapeutic interventions.  
The initial study on human legumain showed high activity at pH values above 6 [27], 
but the stability of the mature legumain was poor above pH 6. However, prolegumain is 
stabile in a neutral environment [27, 31], and functions of legumain in other compartments 
than the lysosomes have therefore been suggested [37, 40, 44]. The subcellular localizations 
of cysteine proteases and endogenous inhibitors seem to be altered in diseases like cancer. For 
example, legumain, cathepsin B and L have recently been observed in the nucleus and are 
suggested to participate in histone degradation [40, 109, 110, 200]. Surprisingly, we detected 
cystatin E/M in the nucleus of cystatin E/M over-expressing M4C cells (paper I). This could 
add to new regulation mechanisms of cysteine proteases. Previously, cystatin B and mutant 
cystatin C (A25T) have also been detected in the nucleus [201-203]. Although cystatin E/M is 
mainly a secreted protein, we showed for the first time that cystatin E/M was internalized and 
subsequently able to inhibit legumain activity intracellularly (paper I). The internalization of 
type 2 cystatins have previously been observed for cystatin C and F [204, 205], and has later 
been verified for cystatin C [206]. This clearly points out that extra- and intracellular 
interactions of the protease and its inhibitors are taking place, which could be of importance 
for the regulation of legumain activity.  
Legumain is synthesized in the ER and transported as the proform to the Golgi 
apparatus. Thereafter, legumain is transported to the lysosomes, where legumain auto-
activates at the presence of low pH. A model of the transport pathways, presumed interplay 
and subcellular localizations of legumain and cystatin E/M is presented below (Fig. 6). This 
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model shows the effects of cystatin E/M, as well as statins, on legumain trafficking and auto-
activation, and will be further discussed below.  
 
 
Figure 6. Model of the cellular localizations of legumain, and the effects of statins and cystatin 
E/M. Legumain is synthesized as an inactive proform (yellow; sleepy smiley) in the ER. Prolegumain 
is transported to the acidic endosomal/lysosomal compartments where it is activated (green; pac-
man). Also, prolegumain can be secreted, interact with the αvβ integrin receptor, activated and 
potentially cleave extracellular substrates as e.g. fibronectin or proMMP-2. The endogenous inhibitor 
of legumain, cystatin E/M (red; triangle), is able to interact with active legumain both extracellularly 
and intracellularly. The suggested effects of statins on legumain trafficking and auto-activation, as 
well as glucose metabolism and ATP-production are also indicated. The pH values are scaled in a red 
color, and lowering of the pH values are illustrated by increasing red color.    
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Secretion of legumain 
 
We observed secretion of prolegumain from over-expressing M38L cells (paper I), 
macrophages (paper II), human myotubes (paper III) and HCT116 cells (paper IV), 
respectively, suggesting that legumain also has functions as an extracellular protease. And, 
surprisingly, legumain (10 ng/ml) was detected in serum from healthy humans (paper II), 
indicating that legumain may be constitutively secreted. It is still poorly understood how 
cysteine proteases are secreted and activated in a neutral environment. However, the 
localization of cathepsin B, L and legumain in association with the plasma membrane and in 
the extracellular space have been addressed in numerous reports [106, 207-209]. Serum 
concentrations of cysteine proteases (cathepsin B, L and S) have been reported [210-212], and 
there are many examples of secreted proenzymes that become activated upon the right stimuli. 
For example, the serine protease thrombin in the coagulation cascade is secreted from 
hepatocytes as prothrombin and activated by factor Xa to the mature enzyme thrombin. It is 
interesting to speculate whether secreted prolegumain could be activated upon exposure to 
e.g. low pH, GAGs or other proteolytic enzymes. The most potent endogenous inhibitor of 
legumain, cystatin E/M, is mainly a secreted protein, indicating requirement for protease 
inhibition extracellularly. Interestingly, extracellular prolegumain seems to be stabilized at 
neutral pH probably due to homodimer formation [32]. Secreted prolegumain from 
macrophages could possibly make homodimers as indicated by gel filtration analysis (Paper 
II). Also, by increasing the pH of the lysosomes using bafilomycin A1 (a vascular H+-ATPase 
inhibitor) increased secretion of prolegumain was observed (paper I), suggesting a switch to 
the exocytotic pathway versus the ER-Golgi-lysosomal pathway after neutralization of the 
lysosomes.  
Auto-activation of prolegumain is initiated by cleavage at Asn323 at low pH. We 
showed that secreted prolegumain is auto-activated at pH 4, and that the auto-activation is 
inhibited by cystatin E/M due to interaction of cystatin E/M and the mature legumain (paper 
I). Recently, it has been suggested that additional cleavage at Lys-Arg-Lys287 is required to 
remove the prodomain from the mature form at low pH (pH~4.5). Interestingly, the cleavage 
at Lys-Arg-Lys287 can take place at pH 6 by adding trypsin, indicating that the activation of 
prolegumain not necessarily is auto-catalytic at low pH (pH~4.5). The auto-activation of 
prolegumain at slightly higher pH (pH 6) has also been observed in vitro in the presence of 
polysaccharides like GAGs and alginates [8, 35]. GAGs have been suggested to interact and 
pull the prodomain away resulting in exposure of the active site and subsequently legumain 
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activity. Since endogenous GAGs are located both extracellularly and intracellularly, they can 
probably facilitate both intra- and extracellular auto-activation of legumain. 
Due to stability issues at neutral pH, mature legumain must be stabilized by other 
proteins to maintain activity in a neutral environment. Recently, association of mature 
legumain with the αvβ integrin receptor increases the pH optimum for activity, indicating 
conformational stabilization of mature legumain by the αvβ integrin receptor at pH values of 
approximately 6 [31]. Also, this can indicate extracellular localization of legumain since the 
αvβ integrin receptor is present on the cell surface. Another opportunity to activate 
extracellular prolegumain can be if the pH is decreased as observed in tumor 
microenvironments [213], in resorptive pits between the osteoclasts and bone (also referred as 
extracellular lysosomes) [214], and in inflammatory acidic microenvironments. Extracellular 
activation of legumain may contribute to ECM degradation, progression of cancer and 
atherosclerosis. 
 
Importance of legumain in macrophages  
 
The ECM must be degraded to promote tumor progression and rupture of atherosclerotic 
plaques. Degradation of ECM is performed by proteases such as the MMPs and the serine 
protease uPA. However, cysteine proteases are also located extracellularly, and are suggested 
to participate in ECM degradation. For example, legumain can promote ECM degradation by 
activation of proMMP-2 [45], processing of cathepsin B, H and L [41], or by direct 
proteolysis of ECM components as shown for fibronectin (Fig. 6) [44]. Also, active forms of 
cathepsin B are secreted from tumor cells [106], cathepsin H from prostate tumor cells [215], 
and cathepsin B, K, L and S from activated macrophages [141, 216]. Prolegumain has been 
reported to be secreted to the acidic tumor microenvironments as well as being associated 
with the αvβ integrin receptor at the tumor cells surfaces [37]. The cells with up-regulated 
legumain levels are in particular tumor cells and the tumor-associated macrophages (TAMs) 
[37, 96]. Recently, TAMs have gained a lot of attention since their presence is associated with 
poor prognosis in cancers [217-219]. TAMs are thought to be one of the key regulators of 
tumor progression and are targets for possible pharmacological interventions [96, 102, 177]. 
TAMs consist primarily of the M2 type macrophages [38, 96] and selective killing of TAMs 
showed reduced tumor growth, expression of angiogenic factors, number of metastasis and 
endothelial cells in murine tumor models [177]. Interestingly, increased levels of active 
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legumain and cathepsin L are also associated with macrophages within unstable 
atherosclerotic plaques [58, 185, 220]. 
Both legumain and cathepsin B were highly expressed during monocyte-to-macrophage 
differentiation (paper II). The striking 500-fold increase in legumain mRNA expression and 
the 72-fold increase in activity during THP-1 cell differentiation suggest that legumain may 
be a potential macrophage differentiation marker (paper II). Legumain have recently been 
suggested as a M2 macrophage marker in murine models [221]. Taking into account the 
observed up-regulation of legumain in macrophages, measurable legumain levels in normal 
sera (paper II), as well as high legumain levels in unstable atherosclerotic plaques [58] and 
solid tumors [37], it is tempting to speculate that quantification of legumain could have 
diagnostic or prognostic value.  
In paper II, we showed that the PMA-stimulated THP-1 macrophages polarized towards 
M2 macrophages, thus mimicking TAMs. Surprisingly, approximately 90 % of the total 
legumain produced from primary M-CSF-differentiated macrophages was secreted as proform 
(paper II). The secretion of prolegumain from macrophages, the presence of legumain in 
human sera (paper II) and subsequently internalization of secreted prolegumain (paper I) in 
neighboring or other cells suggest that prolegumain can function as an “autocrine, paracrine 
or endocrine factor”. The ability to distribute and regulate the amounts of extracellular 
proteolytic enzymes such as prolegumain can support new functions of macrophages. 
Furthermore, the monocytes must enter the site of the tumor or the unstable plaque by 
migration through the endothelial layer and basal membrane. The migration and invasion of 
RAW264.7 macrophages were shown to be inhibited in the presence of cystatin E/M over-
expressing M4C cells compared to native HEK293 and legumain over-expressing M38L cells 
(Fig. 7), indicating cystatin E/M to be an inhibitor of migration and invasion of macrophages. 
Since M38L cells did not affect the motility or migration of RAW264.7 cells, the reduced 
migration of M4C cells was probably due to cystatin E/M or other proteases inhibited by 
cystatin E/M. However, no effects were seen on motility or invasion in similar co-culture 
experiments using TNFα-stimulated THP-1 cells (not shown).  
In conclusion, legumain is secreted and up-regulated during monocyte-to-macrophage 
transition, which could contribute to ECM degradation and subsequently promotion of tumor 
progression and rupture of atherosclerotic plaques. Therefore, any therapeutic interventions 
focusing on legumain by down-regulating or utilizing legumain in a drug targeting strategy 
can be beneficial in e.g. cancer and atherosclerosis (see below). 
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Figure 7. Motility and invasion of RAW264.7 macrophages in presence of legumain over-
expressing (M38L), cystatin E/M over-expressing (M4C) and native HEK293 cells. Radiolabeled 
([methyl-3H] thymidine) RAW264.7 cells were cultured onto transwell permeable plate inserts with a 
polyester membrane coated without (A) or with (B) matrigel for 24 h, before the inserts were added 
to the bottom wells containing either native HEK293, M38L or M4C cells. The co-cultures were 
incubated for 48 hours and then harvested by collecting the RAW264.7 cells by individual swabs on 
each side of the polyester membranes and the radioactivity was counted in a scintillation counter. The 
data are normalized and calculated as radiolabeled cells below the polyester membranes divided by 
cells above the polyester membrane and the mean is presented (± SEM) (n=3, student t-test, 
*p<0.05). 
 
Legumain in pharmacological interventions 
 
Legumain inhibiton by statins 
Statins (HMG-CoA reductase inhibitors) have been shown to prevent cardiovascular disease. 
These drugs does not only affect cholesterol synthesis but have additionally so-called 
pleiotropic effects, including anti-inflammatory effects involving inhibition of macrophage 
proliferation and reduced secretion of MMPs and MCP-1 [149]. Recently, it was 
demonstrated that both cathepsin K and S was down-regulated in aneurysm of the abdominal 
aorta after treatment with either simvastatin or atorvastatin [222, 223]. Furthermore, 
monocytes from patients with hypercholesterolemia treated with atorvastatin, legumain 
mRNA has been shown to be down-regulated [224]. However, so far no previous studies have 
investigated legumain expression or activity after statin exposure. Thus, in paper II and III 
we showed decreased protein expression, processing, activity and secretion of legumain by 
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two statins (atorvastatin and simvastatin, respectively) in macrophages and myotubes. Similar 
effects of simvastatin were observed in legumain over-expressing M38L cells, showing 
reduced legumain activity and processing (Fig. 8), indicating this to be a general phenomenon 
of statins. All cell models used in our studies responded in a similar manner to the treatment 
with atorvastatin or simvastatin by loss of legumain activity, although at different statin 
concentrations but independent of statin forms (acid or lactone form). The legumain inhibitory 
effects observed by statins as well as inhibition of cathepsin B activity in macrophages and 
myotubes (paper II and III) may contribute to both the beneficial and adverse effects of 
these drugs in patients. For example, down-regulation of legumain in macrophages could 
potentially add to the pleiotropic effect of statins, since legumain is suggested to participate in 
plaque destabilization by degradation of ECM. On the other hand, the cellular effects of 
statins seem to be distinct since toxic effects on skeletal muscle often is reported. Therefore, 
down-regulation of legumain by statins in myotubes could be unfavorable and potentially 
involved in statin-induced myotoxicity.  
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Figure 8. Inhibition of legumain by simvastatin in legumain over-expressing M38L cells. 
Legumain over-expressing HEK293 cells (clone M38L; 0.1 mill.) were cultured for 24 h with 
simvastatin (0–100 μM) before cell lysates and corresponding serum-free conditioned media were 
collected. A. Legumain activity measured in the cell lysates (±SEM) and normalized to untreated 
control (n=3, with duplicates). B. Immunoblots of equal volumes of conditioned media (upper panel) 
or cell lysates (12.5 μg total protein/well; middle panel) were prepared and antibody against legumain 
(upper and middle panels) was used. GAPDH (lower panel) was used as loading control of cell 
lysates. 
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The down-regulation of legumain activity and accumulation of the proform observed after 
treatment with statins could possibly be explained by several mechanisms. Since the proform 
auto-activates at acidic pH, it is likely that the proform is not located in the acidic lysosomes 
or that the lysosomes were less acidic after statin treatment. Cholesterols in the lipid bilayer 
regulate membrane fluidity, however, no vesicle leakage of legumain was observed (paper 
III), possibly excluding legumain translocation since activity is expected to be abolished at 
neutral pH [27]. Another possibility is reduced intracellular transport of newly synthesized 
prolegumain molecules to the lysosomes, resulting in an accumulation of the proform in 
intracellular vesicles with neutral pH. Interestingly, geranylgeranyl-PP has been shown to 
prevent decreased prenylation of Rab1 GTPase caused by fluvastatin [225], thereby inhibiting 
vesicular transportation from ER to Golgi. In paper II, both down-regulation of legumain 
activity and expression of the 36 kDa mature form caused by simvastatin were partly or fully 
prevented by geranylgeranyl-PP or mevalonolactone (ML), respectively, indicating that 
inhibition of prenylation of small GTPases possibly could account for some of the effects 
observed. Cholesterol depletion by statins could potentially lead to dysfunctional trafficking 
of vesicles, due to improper subcellular compartmentalization of phosphoinositides [226-228].  
The accumulation of prolegumain caused by statins (paper II and III) was similar to the 
effects observed by treatment with bafilomycin A1 (paper I). Interestingly, re-ligation of 
active legumain with the C-terminal prodomain by increasing the pH has recently been 
reported [32], and could also explain the accumulation of the proform observed in paper II 
and III. The effects of legumain observed by increasing the pH led us to hypothesize that 
statins can increase the pH in the lysosomes. 
Furthermore, glucose intolerance has been observed in tumor cells after exposure to 
statins [229]. Also, mitochondrial dysfunction was observed in patients taking statins [230], 
and was in line with the coenzyme Q10 hypothesis stating that decreased Q10 synthesis was 
responsible for the effects [231, 232]. Both uptake and oxidation of glucose was decreased 
after simvastatin treatment of the myotubes (paper III), and this effect could result in reduced 
cellular ATP, subsequently dysfunctional vacuolar type H+–ATPase and increased pH of the 
lysosomes (Fig. 6). Interestingly, extracellular glucose has been reported to decrease the 
activity of cathepsin B, D, L and S in human monocytes and murine macrophage-like J774A.1 
[233]. On the contrary, our results show enhanced legumain activity by high glucose 
concentrations (hyperglycemia, >5.5 mM glucose) compared to normoglycemia (5.5 mM 
glucose; Fig. 9). On the other hand, decreased legumain activity was observed by reducing the 
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glucose concentration (hypoglycemia, <5.5 mM glucose; Fig. 9). These results indicate that 
glucose could regulate functions of lysosomal enzymes such as legumain and could be 
important in diseases like diabetes. Interestingly, legumain is highly expressed in the kidney 
and diabetes is often associated with kidney failure [27]. It is tempting to speculate that 
hyperglycemia observed in diabetes could increase the activity of legumain, thus enhancing 
degradation of the kidney tissue and subsequently development of kidney failure.     
0 5 10 15 20 25 30
0
10
20
30
40
250
500
750
1000
1250
M38L
HEK293
Normo
HyperHypo
Glycemia state:
Glucose (μM)
Le
gu
m
ai
n 
ac
tiv
ity
/ μ
g 
to
ta
l p
ro
te
in
('
F/
s)
 
Figure 9. The glucose level regulates legumain activity in native HEK293 and legumain over-
expressing M38L cells. Cells were cultured (50,000 cells/well) in 6-well plates and incubated for 6 
days with different concentrations of glucose. The cells were harvested and legumain activity was 
measured using the substrate Z-Ala-Ala-Asn-AMC (n= 4-7). 
 
Utilizing legumain in drug targeting 
A legumain-cleavable prodrug was synthesized by conjugating colchicine to the peptide Val-
Asn-Ala-Ala-Suc (Fig. 10) (paper IV). All of the reported prodrugs utilizing legumain have 
in common the legumain-cleavable peptide sequence Ala-Ala-Asn. The physiochemical 
properties of a drug are changed by adding a peptide sequences to a lipophilic drug such as 
colchicine. It becomes more hydrophilic and less cytotoxic by adding the protease-cleavable 
peptide connected by an amino acid linker. For example, the use of the lipophilic drug 
colchicine conjugated with a cathepsin B-cleavable peptide made it more hydrophilic and 
showed cell specific toxicity [171]. The legumain-cleavable prodrug (colchicine-Val-Asn-
Ala-Ala-Suc) was more hydrophilic and less cell toxic. Thus, higher doses of the Suc-Ala-
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Ala-Asn-Val-colchicine prodrug were needed to observe cell toxicity. This prodrug was 
cleaved by legumain, resulting in the release of the cytotoxic valyl colchicine (Fig. 10) (paper 
IV).  
 
 
 
 
Figure 10. Synthesis of a legumain-cleavable colchicine prodrug (Suc-Ala-Ala-Asn-Val-
colchicine) with cell specific toxicity. The prodrug is cleaved by legumain, resulting in release of 
cytotoxic valyl colchicine. The legumain cleavage site is marked by a red arrow. 
 
It might be suggested that this prodrug could have beneficial therapeutic effects by selective 
prodrug cleavage in legumain over-expressing macrophages in atherosclerotic unstable 
plaques as well as in tumors [58, 185, 220]. The prodrug approach presented in our study 
could reduce the general toxicity and increase specificity of colchicine, thus extend its use 
against inflammation and e.g. be a possible candidate for chemotherapeutic eradication of 
tumors. 
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CONCLUSION 
 
The novel and main findings in present work are summarized as follows: 
x Secreted legumain is internalized by cells and subsequently processed and activated 
(paper I). 
x Legumain activity is regulated by cystatin E/M both intra- and extracellularly (paper I). 
x Cystatin E/M is present in the cell nucleus (paper I).  
x Prolegumain is highly secreted from monoclonal legumain over-expressing M38L cells, 
macrophages, myotubes and HCT116 colorectal cancer cells (paper I, II, III and IV). 
x The major part (90 %) of the total legumain produced in human primary M-CSF-
differentiated macrophages is secreted as proform (paper II). 
x Legumain is detectable in human sera (paper II). 
x Legumain activity and expression are highly up-regulated during monocyte-to-
macrophage differentiation, and legumain may be used as a macrophage differentiation 
marker (paper II). 
x Legumain activity, expression, and secretion are inhibited by statins (HMG-CoA 
reductase inhibitors) in the cell types studied and may be a general phenomenon (paper II 
and III).  
x Statins are able to inhibit legumain activation, probably by interference with the vesicular 
intracellular trafficking and/or by increasing the pH of the lysosomes. Inhibition of the 
HMG-CoA-reductase seems to be responsible for the reduction of legumain expression 
and activity induced by simvastatin (paper III). 
x A new legumain-cleavable colchicine prodrug (Suc-Ala-Ala-Asn-Val-colchicine) is 
shown to be less cytotoxic than valyl colchicine or colchicine (paper IV).  
x The legumain-cleavable colchicine prodrug has cell-specific toxicity towards cells over-
expressing active legumain and could possibly be used in cell targeting (paper IV).  
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Abstract
Simvastatin, a HMG-CoA reductase inhibitor, is prescribed worldwide to patients with hypercholesterolemia. Although
simvastatin is well tolerated, side effects like myotoxicity are reported. The mechanism for statin-induced myotoxicity is still
poorly understood. Reports have suggested impaired mitochondrial dysfunction as a contributor to the observed
myotoxicity. In this regard, we wanted to study the effects of simvastatin on glucose metabolism and the activity of
legumain, a cysteine protease. Legumain, being the only known asparaginyl endopeptidase, has caspase-like properties and
is described to be involved in apoptosis. Recent evidences indicate a regulatory role of both glucose and statins on cysteine
proteases in monocytes. Satellite cells were isolated from the Musculus obliquus internus abdominis of healthy human
donors, proliferated and differentiated into polynuclear myotubes. Simvastatin with or without mevalonolactone, farnesyl
pyrophosphate or geranylgeranyl pyrophosphate were introduced on day 5 of differentiation. After 48 h, cells were either
harvested for immunoblotting, ELISA, cell viability assay, confocal imaging or enzyme activity analysis, or placed in a fuel
handling system with [14C]glucose or [3H]deoxyglucose for uptake and oxidation studies. A dose-dependent decrease in
both glucose uptake and oxidation were observed in mature myotubes after exposure to simvastatin in concentrations not
influencing cell viability. In addition, simvastatin caused a decrease in maturation and activity of legumain. Dysregulation of
glucose metabolism and decreased legumain activity by simvastatin points out new knowledge about the effects of statins
on skeletal muscle, and may contribute to the understanding of the myotoxicity observed by statins.
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Introduction
Simvastatin, a HMG-CoA reductase inhibitor (statin), is
prescribed worldwide to patients with hypercholesterolemia to
prevent cardiovascular disease and death [1,2]. Although
simvastatin is well-tolerated, side effects like myotoxicity have
been reported, ranging from fatigue to life-threatening rhabdo-
myolysis [3,4]. Several hypotheses explaining the statin-induced
myotoxicity have been put forward, but the underlying mechanism
is still poorly understood. The mechanisms for statin-induced
myotoxicity are probably multifactorial and at least partly due to a
combination of impaired isoprenylation of trafficking proteins
[5,6], altered Ca2+ homeostasis [7] and impaired mitochondrial
respiratory function [8–10]. The mitochondrial respiratory dys-
function observed in statin-treated patients caused glucose
intolerance [10]. Also, glucose intolerance was observed in tumor
cells after exposure to statin, resulting in decreased glucose uptake
and a higher glucose concentration in the conditioned cell medium
[11]. Regarding impaired mitochondrial function, many biochem-
ical processes are affected by impaired glucose oxidation and low
ATP production, like the activity of the lysosomal H+-ATPase, pH
of the lysosomes and processing of lysosomal proteases.
Legumain (asparaginyl endopeptidase) is a cysteine protease
mainly localized to the lysosomes and was first characterized in
mammals in 1997 [12]. Legumain is ubiquitously expressed in
mammalian tissue [12], and over-expression is associated with
atherosclerotic plaque instability and cancer malignancy [13,14].
In cancer malignancy legumain has been reported to translocate
from the lysosomes to the cell nucleus [15]. Legumain has also
been described to participate in apoptosis of Blastocystis and neural
cells of mice [16,17]. Furthermore, legumain contributes to the
maturation process of cathepsin B and L, two other cysteine
proteases [18]. Recently, down-regulation of legumain mRNA in
macrophages caused by atorvastatin has been reported as well as
decreased cathepsin L activity in statin-treated patients with aortic
aneurysms [19,20]. Legumain cleaves peptide bonds carboxy-
terminally to asparagine, as well as at aspartate residues at pH
below 5 and thus acquiring caspase-like properties [13,21]. The
protease is expressed as a 56 kDa proform, which is autoactivated
at acidic pH to 47/46 kDa intermediate forms [22]. The
intermediate legumain forms are further enzymatically processed
to the mature active 36 kDa form. Also, prolegumain has been
reported to be secreted as well as being associated with integrins
[13], and can be internalized and subsequently autoactivated [23].
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Although the biological and pathological roles of legumain are
starting to be elucidated, much is still unknown. Interestingly,
increasing the concentration of glucose to the media of human
monocytes and murine macrophage-like J774A.1 cells are
reported to down-regulate the activity of cathepsin B, D, L and
S [24], thus indicating an interesting regulatory role of glucose on
lysosomal enzymes.
The overall aim of this study was to investigate effects of
simvastatin on glucose metabolism in human myotubes. Skeletal
muscles are the major organ for glucose metabolism, and any
alteration caused by simvastatin on glucose metabolism in human
myotubes could shed light on mechanisms involved in adverse
effects and toxicity of statins. Also, the effects of simvastatin on
regulation of the cysteine protease legumain were studied in this
context.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM-GlutamaxTM,
5.5 mM glucose), foetal bovine serum, Ultroser G, penicillin–
streptomycin (P/S), amphotericin B, DAPI, XCell SureLockH
Mini, NOVEX Tris-Glycine Native Sample Buffer (2X), NOVEX
Tris-Glycine Native Running buffer (10X), NuPAGE Bis-Tris 4–
12% gels, NuPAGE MOPS SDS running buffer (20X), NuPAGE
LDS sample buffer (4X), AlexaH568 donkey anti-mouse (cat. no.
A10037), AlexaH488 donkey anti-goat (cat. no. A11055) and
ProLongH Gold antifade reagent with DAPI (cat. no. P36935)
were obtained from Life Technologies (Paisley, UK). [14C-
(U)]glucose (107.3 GBq/mmol), [3H]deoxyglucose (37 MBq/ml)
and [1-14C]oleic acid (2 GBq/mmol) were purchased from
PerkinElmer NENH (Boston, MA, USA). Simvastatin was obtained
from Toronto Research Chemicals (Ontario, Canada). Insulin
Actrapid was from Novo Nordisk (Bagsvaerd, Denmark). Culture
plates (6-, 12- and 96-wells) and 25 cm2 flasks were obtained from
Corning Life-Sciences (Schiphol-Rijk, The Netherlands). Opti-
Phase Supermix and UniFilterH-96 GF/B were delivered by
PerkinElmer (Shelton, CT, USA). CHAPS, DL-dithiotreitol
(DTT), trypan blue, triton X-100, mevalonolactone, geranylger-
anyl pyrophosphate ammonium salt, farnesyl pyrophosphate
ammonium salt, rotenone, oligomycin A, carbonyl cyanide 4-
(trifluoromethoxy)-phenylhydrazone (FCCP) and antimycin A
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Sodium pyruvate solution, foetal calf serum (FCS) and trypsin-
EDTA were purchased from PAA Laboratories GmbH (Pasching,
Austria). Nitrocellulose membranes were from Hybond ECL
(Amersham Biosciences, Boston, MA, US). Cytoslides (cat.
no. 154534), SuperSignal West Dura Extended Duration Sub-
strate and Restore Western Blot Stripping Buffer were purchased
from Thermo Fisher Scientific (Rockford, IL, USA). Protein assay
reagent, Tween 20, SDS, Precision plus protein standards, goat
anti-rabbit IgG HRP-conjugate (cat. no. 170-6515) and goat anti-
mouse IgG HRP-conjugate (cat. no. 170-6516) were purchased
from BioRad (Copenhagen, Denmark). Goat anti-human legu-
main (cat. no. AF2199), goat anti-human cathepsin L (cat. no.
AF952), goat anti-human cathepsin B (cat. no. AF953) and mouse
anti-human arylsulfatase B (cat. no. MAB4415) were purchased
from R&D Systems (Abingdon, UK). MitoProfileH Total OX-
PHOS Human WB Antibody Cocktail (cat. no. ab110411) and
rabbit anti-human GLUT1 (cat. no. ab15309) were from Abcam
(Cambridge, UK). Rabbit anti-goat IgG HRP-conjugate (cat. no.
P0160) was purchased from DAKO (Glostrup, Denmark), whereas
mouse anti-human a-tubulin (cat. no. CP06) was obtained from
Calbiochem (San Diego, CA, USA). Mouse anti-human GAPDH
(cat. no. sc-47724) and mouse anti-human LAMP-2 (sc-18822)
were from Santa Cruz (Heidelberg, Germany). Z-Arg-Arg-AMC
and Z-Ala-Ala-Asn-AMC were purchased from Bachem (Buben-
dorf, Switzerland). Non-fat dry milk was from Normilk (Levanger,
Norway). Qproteome Cell Compartment Kit was purchased from
Qiagen (Hilden, Germany). CellTiter 96H aqueous one solution
cell proliferation assay (MTS assay) was obtained from Promega
(Madison, Wisconsin, USA). All other chemicals used were
standard commercial high-purity quality.
Ethics Statement
The biopsies were obtained with informed written consent and
approval by the Regional Committee for Medical and Health
Figure 1. Reduced glucose uptake in myotubes after treatment
with simvastatin. A and B. Differentiated myotubes were incubated
for 48 h with simvastatin (S) with or without mevalonolactone (1 mM;
ML) and compared to untreated control (C), prior to incubation with
radiolabeled substrates at day 7. A. Dose-response of simvastatin on
glucose uptake after 4 h incubation with [14C(U)]glucose (0.2 mM,
21.5 kBq/ml) using a multiwell trapping device. Radioactivity was
measured in cell lysates and in trapped CO2 and corrected for total
proteins (n = 3–8, student t-test, *p,0.05 vs. untreated). B. Effects of
5 mM simvastatin with or without ML on uptake of [3H]deoxyglucose
(10 mM, 37 kBq/ml, 15 min) (n = 3, student t-test, *p,0.05 vs. S). C.
Differentiated myotubes were pre-incubated for 48 h with simvastatin
(30 mM) before subcellular fractionation. Equal amount of total proteins
from the membrane fraction were loaded to the gel and immunoblot
analysis performed. LAMP-2 was used as loading control. Quantification
of GLUT1 band intensity is shown, corrected for LAMP-2 and normalized
to untreated control (C) (n = 4). D. Myotubes were treated with 0–
40 mM simvastatin with or without 50 mM or 1 mM ML for 48 h before
cell viability was analyzed at day 7. The cells were incubated with MTS-
reagent for 2 h before absorbance at 490 nm was measured (n = 3,
student t-test, *p,0.05 vs. untreated control (C)).
doi:10.1371/journal.pone.0085721.g001
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Figure 2. Effects of simvastatin on glucose oxidation and expression of proteins involved in oxidative phosphorylation. A and B.
Differentiated myotubes were pre-incubated for 48 h with simvastatin (A: 0–20 mM; B: 5 mM) prior to incubation for 4 h with [14C(U)]glucose
(0.2 mM, 21.5 kBq/ml) with or without different agents at day 7. A. Dose-response of simvastatin on glucose oxidation with or without addition of
FCCP (1 mM; n= 3). B. Effects on glucose oxidation of 0.1 mM rotenone, 0.1 mM antimycin A, 1 mg/ml oligomycin A or 1 mM FCCP with (black bars) or
without (open bars) simvastatin. Radiolabeled [14C]CO2 was trapped and counted in a MicroBetaH scintillation counter and corrected for total protein
(n = 4–8, student paired t-test, *p,0.05 vs. basal). C. One representative immunoblot of proteins involved in oxidative phosphorylation from
differentiated myotubes incubated for 48 h with (S) or without (C) 10 mM simvastatin is shown. Twenty mg total proteins were loaded to the gel and
immunoblot analysis using MitoProfileH Total OXPHOS Human WB Antibody Cocktail and GAPDH were performed (n = 3).
doi:10.1371/journal.pone.0085721.g002
Figure 3. Legumain activity and expression after treatment with simvastatin, mevalonolactone, geranylgeranyl pyrophosphate
and/or farnesyl pyrophosphate. Differentiated myotubes were incubated for 48 h with simvastatin (0–40 mM) with or without mevalonolactone
(50 or 1000 mM; ML), geranylgeranyl pyrophosphate (3 mM; GGPP) or farnesyl pyrophosphate (3 mM; FPP) prior to harvesting at day 7. A. Dose-
dependent effects of simvastatin (0–40 mM) on legumain activity (n = 3–15, student t-test, *p,0.05 vs. 0 mM). B. Effects on legumain activity caused
by 30 mM simvastatin (S alone) with or without ML, GGPP or FPP. The data are compared and normalized to untreated myotubes (n = 6–12, student t-
test, *p,0.05 vs. S alone; n = 12, paired student t-test, #p,0.01 vs. untreated). C. Effects on legumain expression caused by 30 mM simvastatin (S
alone) with or without ML, GGPP or FPP. Equal amounts of total proteins (10 mg) of cell lysates were separated and immunoblot analyzes were
performed. One representative immunoblot is shown and band intensity analysis are normalized to 36 or 56 kDa legumain immunobands,
respectively, (n = 4–7, student t-test, *p,0.05 vs. S alone).
doi:10.1371/journal.pone.0085721.g003
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Research Ethics (Oslo, Norway). The research performed in this
study was approved, as a part of a larger project, by the Regional
Committee for Medical and Health Research Ethics (Oslo,
Norway).
Cell Culturing
Satellite cells were isolated from the Musculus obliquus internus
abdominis of healthy human donors with no history of statin
treatment. The cells were isolated, cultured, proliferated and
differentiated as described elsewhere [25]. Briefly, cells were
cultured in wells or flasks at a density of approximately 5000–
30000 cells/cm2 in medium containing DMEM-Glutamax
(5.5 mM glucose), 10% FCS, 50 units/ml penicillin/streptomycin
(P/S) and 1.25 mg/ml amphotericin B. This medium was
substituted after one day with medium containing DMEM-
Glutamax, 2% FCS, 2% Ultroser G, 50 units/ml P/S and
1.25 mg/ml amphotericin B and changed every 2–3 days until 80–
90% confluence. Myoblast differentiation to myotubes was then
induced by changing medium to DMEM-Glutamax with 2% FCS,
34 pM insulin, 50 units/ml P/S and 1.25 mg/ml amphotericin B.
The cells were cultured, proliferated and differentiated in
humidified 5% CO2 atmosphere at 37uC. Incubation with 0–
40 mM simvastatin with or without 0.05 or 1 mM mevalonolac-
tone (ML), 3 mM farnesyl pyrophosphate (FPP) or 3 mM
geranylgeranyl pyrophosphate (GGPP) in the differentiation
medium were introduced on day 5 of differentiation. After 48 h
of incubation, cells were either harvested in lysis buffer containing
100 mM sodium citrate, 1 mM disodium-EDTA, 1% n-octyl-b-D-
glucopyranoside, pH 5.8 or used for further experiments described
later. Cell lysates were freeze-thawed 3 times before analysis by
immunoblotting, enzyme activity and total protein measurements.
Total protein concentrations were determined by a procedure
described elsewhere [26] and standard curves were established
using albumin.
Cysteine Protease Activity Measurements
Legumain activity was measured by recording the cleavage of
the peptide substrate Z-Ala-Ala-Asn-AMC. Briefly, 20 ml of cell
lysate was added to black 96-well microtiter plates. A kinetic
measurement based on increase in fluorescence over 10–60 min
was performed after addition of 100 ml legumain assay buffer and
50 ml peptide substrate solution (10 mM Z-Ala-Ala-Asn-AMC)
described elsewhere [12,27].
Cathepsin B activity was measured in a similar way except of
using the peptide substrate Z-Arg-Arg-AMC. Briefly, 20 ml of cell
lysate was added to black 96-well microtiter plates. Cathepsin B
assay buffer [28,29] and peptide substrate solution (20 mM Z-Arg-
Arg-AMC) was added and fluorescence measured. Temperature
was kept at 30uC and all measurements were done in triplicate.
Linarites of the assays were established by measuring the initial
substrate cleavage rates and limiting the substrate consumption to
less than 2% during the measurements. Enzyme activity is
presented as unit/mg total proteins (mmol/(min?mg)).
Immunoblotting
Samples of cell lysate were prepared for NuPAGE electropho-
resis according to the manufacturer’s recommendations (Life
Technologies). Briefly, samples were mixed with 0.5 M DTT and
NuPAGE LDS sample buffer and run along with 5 ml Precision
plus protein standard on NuPAGE 4–12% gels in a container with
NuPAGE MOPS SDS running buffer. Blotting was performed
using 20% methanol, 25 mM Tris, and 0.2 M glycine, pH 8.3.
Nitrocellulose membranes were blocked with 5% non-fat milk in
Tris-buffered saline containing 0.05% Tween 20 (TBS-T) for 1–
2 h at room temperature, and then incubated overnight at 4uC
with goat anti-human legumain (1:1000), goat anti-human
cathepsin B (1:10000), goat anti-human cathepsin L (1:5000),
mouse anti-human GAPDH (1:10000), mouse anti-human LAMP-
2 (1:500), mouse anti-human a-tubulin (1:5000), rabbit anti-
human GLUT1 (1:1000), mouse anti-human total OXPHOS
cocktail (1:500) or mouse anti-human arylsulfatase B (ARSB;
1:500). Further incubation for one hour was performed with
appropriate HRP-conjugate of secondary antibodies. After four
ten-minute washes in TBS-T, immunoreactive bands on the
membranes were detected by SuperSignal West Dura Extended
Duration Substrate. Membranes were reprobed after stripping in
Restore Western Blot Stripping Buffer as described by the
manufacturer (Thermo Fisher Scientific). Immunoband intensities
were analyzed by Image 4.0 (BioRad).
Confocal Imaging
Cells (56104) were seeded on cytoslides, cultured, differentiated
and treated as described above. On day 7 after start of
differentiation, cells were fixed with 4% paraformaldehyde in
PBS for 10 min on ice and washed twice in PBS before being
permeabilized for 5 min with 0.2% Triton X-100. Cells were
washed three times with PBS, 0.1% BSA, 0.2% Triton X-100 and
0.05% Tween 20, and then blocked with 10% horse serum for 1 h.
Then, immunocytochemical staining was performed using goat
anti-human legumain (1:50) or goat anti-human cathepsin B
(1:100) and mouse anti-human ARSB (1:50) primary antibodies
for 1 h. After three washes, corresponding secondary antibodies
were applied (donkey anti-goat; Alexa 488; 1:250 or donkey anti-
mouse; Alexa 568; 1:500, respectively). The coverslips were
mounted in ProLong Gold antifade reagent with DAPI. The cells
were observed using a laser-scanning confocal imaging system
LSM710 (Carl Zeiss) with equal settings in all experiments.
Figure 4. Legumain, cathepsin B and L expressions in cytosolic
and membrane fractions of myotubes. Myotubes were treated
with (+) or without (2) 30 mM simvastatin for 48 h before subcellular
fractionation was performed. One representative immunoblot of
legumain, cathepsin B and L in the cytosolic and membrane fractions
is shown. All lanes were loaded with equal amount of total proteins and
probed with antibodies as indicated. LAMP-2 and a-tubulin are shown
as cell compartment controls (n = 3).
doi:10.1371/journal.pone.0085721.g004
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ELISA
Established ELISA procedure given by the manufacturer was
performed to measure the concentrations of legumain (R&D
Systems; MAB21992) in conditioned media from myotubes.
Cell Viability (MTS)
Cell viability assays were carried out using the manufacturer’s
protocol. Briefly, 56104 cells were cultured, proliferated, differ-
entiated and treated with simvastatin in quadruplicates in 96-wells
culture plates. After 24 h, 20 ml of 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS reagent) were added to each well and incubated for 2 h
before absorbance was measured at 490 nm in a microplate
reader, Wallac Victor3 (PerkinElmer).
Subcellular Fractionation
Samples of different subcellular fractions were prepared using
the Qproteome Cell Compartment Kit according to the manu-
facturer’s protocol. Purity of fractions was checked with a-tubulin,
LAMP-2, ARSB and Lamin B as cytosolic, membrane, soluble
membrane and nuclear markers, respectively.
Uptake and Oxidation of Glucose
Cells were cultured, proliferated and differentiated on 96-well
CellBINDH microplates. First, 48 h incubation with simvastatin
was started on day 5 of differentiation before analysis with cell-
based multiwell assay was performed as described elsewhere [30].
Briefly, medium was removed before addition of [14C-(U)]glucose
(37 kBq/ml, 0.2 mM) in Dulbecco`s PBS (DPBS) with 10 mM
HEPES, containing either 0.1% DMSO, 0.1 mM rotenone, 1 mg/
ml oligomycin A, 0.1 mM antimycin A, or 1 mM FCCP. A 96-well
UNIFILTERH microplate presoaked with 20 ml 1 M NaOH was
mounted on top of the CellBINDH plate, and the cells were
incubated at 37uC and 5% CO2 for 4 h. The CO2 trapped in the
filter was then counted by liquid scintillation in a MicroBetaTM
Trilux scintillation counter (PerkinElmer). The remaining cell-
associated radioactivity was also assessed by liquid scintillation,
and the formation of CO2 and cell-associated radioactivity was
considered as total glucose uptake while the formation of CO2 was
considered as glucose oxidation.
Uptake of Deoxyglucose
The cells were cultured, proliferated and differentiated on 12-
well plates. First, 5 days after onset of differentiation, treatment
with 5 mM simvastatin with or without 1 mM ML were added.
After 48 h of incubation, the cells were washed and incubated for
1 h with 140 mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM
MgSO4 and 1 mM CaCl2, pH 7.4, before [
3H]deoxyglucose
(37 kBq/ml, 10 mM) was added and incubated for 15 min. Then
cells were washed 3 times with PBS and harvested in 250 ml 0.1 M
NaOH. The lysates were counted by liquid scintillation.
Statistics
The data are represented as mean 6 SEM. Student t-test or
student paired t-test were performed when appropriate, and
statistical significance was considered at p,0.05. All experiments
were performed on cells from at least three donors and at least
triplicate measurements.
Results
Simvastatin Reduced Glucose Uptake and Oxidation in
Human Myotubes
Previous reports have shown that simvastatin reduces glucose
metabolism both in cancer cells and adipocytes [11,31]. In our
study using differentiated human myotubes, simvastatin signifi-
cantly reduced uptake of [14C]glucose in a dose-dependent
manner with an IC50 value of approximately 8 mM (Fig. 1A).
The myotubes seemed to be more sensitive to reduced glucose
uptake by simvastatin than the embryonic kidney cell line
HEK293. Whereas 5 mM simvastatin significantly decreased
glucose uptake in the myotubes, no effect was observed in the
HEK293 cells (Fig. S1). Reduced glucose uptake caused by 5 mM
simvastatin was confirmed using [3H]deoxyglucose giving approx-
imately 45% less uptake (Fig. 1B). Treatment with a combination
of simvastatin and mevalonolactone (ML; 1 mM) totally prevented
the decreased deoxyglucose uptake (Fig. 1B). Since the experi-
ments were done in absence of insulin and GLUT1 is the
predominant glucose transporter in human myotubes [32], the
GLUT1 expression after exposure to simvastatin was studied. The
observed effects of simvastatin were not due to differences in
GLUT1 expression (Fig. 1C). To verify that the observed effects of
simvastatin were not due to cell death of myotubes, cell viability,
total proteins concentrations and caspase-3 expression were
studied. There were no differences in cell viability (Fig. 1D), total
protein concentrations (Fig. S2A) or immunoband of active
caspase-3 (Fig. S2B) after simvastatin treatment.
Knowing that the myotubes were fully viable at the simvastatin
concentrations used, the observed reduction in glucose uptake
could be an indirect effect of impaired oxidation of glucose.
Therefore, an uncoupler of oxidative phosphorylation (FCCP) was
introduced and shown to increase oxidation of glucose by
approximately 3-fold. This reflected a high reserve capacity for
glucose oxidation in myotubes, calculated as the difference
between oxidation in the presence or absence of FCCP (Fig. 2A).
The reserve capacity for glucose oxidation after simvastatin (5 mM)
treatment was reduced by approximately 40% (Fig. 2A). To
further study the mechanism of simvastatin (5 mM) on oxidative
phosphorylation, different inhibitors of the respiratory chain and
ATP formation were introduced. Rotenone, oligomycin A, and
antimycin A were used to inhibit complex I, ATP synthase and
complex III, respectively. No significant effects on glucose
oxidation were observed in myotubes treated with any of these
agents with or without simvastatin, whereas treatment with FCCP
reflected the observation already described above (Fig. 2B).
Finally, the effects of simvastatin on the expression of complex I,
complex II subunit 30 kDa, complex III core 2, complex IV and
ATPase-a-subunit were studied. No significant differences were
observed, but there was a tendency of reduced expression of
complex I-IV of the respiratory chain by simvastatin (Fig. 2C; Fig.
S3).
Reduced Legumain Activity and Expression in
Simvastatin-treated Myotubes
The glucose concentration in the cell culture media has been
reported to regulate the activity of cathepsin B, D, L and S in
human monocytes and murine macrophage-like J774A.1 cells
[24]. Also, atorvastatin has been shown to decrease legumain
mRNA in monocytes [20]. Since glucose metabolism was
decreased in human myotubes after exposure to simvastatin
(Fig. 1, 2), this interesting regulatory role of glucose on lysosomal
enzymes led us to investigate whether legumain was affected by
simvastatin in human myotubes. Initially, expression and activity
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of legumain were studied during myotube differentiation and
compared to cathepsin B, which is reported to participate in
myotube differentiation [33,34]. Undifferentiated myoblasts (dif-
ferentiation day 0) showed both legumain and cathepsin B activity
at a level of 0.9 (60.2) and 5.8 (61.1) mUnit/mg, respectively.
Legumain activity was significantly increased both at differentia-
tion day 2 and 5 compared to day 0 (Fig. S4A). Increased activity
was due to increased expression of the mature active form
(36 kDa) as reflected by immunoblotting (Fig. S4B and C).
Cathepsin B activity and expression of the active two-chain form
(23 kDa) also showed increasing tendencies throughout myotube
differentiation (Fig. S4A, B and D).
Treatment of myotubes on day 5 of differentiation with
increasing concentrations of simvastatin for 48 h showed reduced
legumain activity in a dose-dependent manner with an IC50 value
of about 25 mM (Fig. 3A). There was also a tendency of reduced
cathepsin B activity caused by increasing simvastatin concentra-
tion (data not shown). To study whether inhibition of the HMG-
CoA reductase was involved in the reduced legumain activity
observed by simvastatin, intermediates of the mevalonate pathway
including mevalonolactone (ML), geranylgeranyl pyrophosphate
(GGPP) and farnesyl pyrophosphate (FPP) were introduced. The
effect of simvastatin (30 mM) on legumain activity was partly
prevented by ML (1 mM) or FPP (3 mM; Fig. 3B). Also, the
legumain activity measurement was reflected by the expression of
the 36 kDa immunoband, representing the mature active form,
which was significantly reduced after treatment with simvastatin
alone (Fig. 3C, S alone). In addition, a concomitant accumulation
of the 56 kDa immunoband was seen, reflecting reduced
prolegumain processing. No significant changes were observed
by addition of ML, GGPP or FPP (Fig. 3C). Furthermore, fully
differentiated myotubes secreted legumain to the conditioned
media at a rate of 0.02 (60.005) pg/cell/day, and the secretion
was not affected by treatment with simvastatin (30 mM).
To study whether simvastatin could alter the intracellular
distribution of lysosomal cysteine proteases, subcellular compart-
ments of myotubes were isolated and analyzed for legumain,
cathepsin B and L. Immunoblots showed that both legumain,
cathepsin B and L in untreated myotubes were located only in the
membrane compartment, comprising cytoplasmic organelles
(Fig. 4). After simvastatin treatment, there was no altered
subcellular localization of either legumain, cathepsin B or L, as
no immunbands were detected in the cytosolic (Fig. 4) or nuclear
compartments (data not shown). Subcellular compartment purities
were verified by LAMP-2 (membranes), a-tubulin (cytosol) and
lamin B (nucleus; not shown), respectively. Simvastatin (30 mM)
reduced the expression level of the mature form of legumain
(36 kDa) as well as increased the level of prolegumain (56 kDa) in
the membrane fraction, confirming the observation in whole
myotube lysates (Fig. 3). Also, subcellular presence of legumain
and cathepsin B was confirmed by confocal imaging. Legumain
seemed to be co-localized in lysosomes with arylsulfatase B (ARSB,
a soluble lysosomal enzyme) in untreated myotubes (yellow; Fig.
S5A) and treatment with simvastatin did not seem to alter
legumain distribution (Fig. S5B). Cathepsin B also seemed to be
vesicular although not distinctly co-localized with ARSB (Fig.
S5C), and simvastatin caused a more diffuse staining (Fig. S5D).
Discussion
In this study we observed decreased uptake and oxidation of
glucose in human myotubes caused by treatment with
simvastatin. Also, legumain (a cysteine protease) was for the
first time characterized in human myotubes and decreased
legumain activity and expression was observed by simvastatin.
The reduction in legumain activity was caused by decreased
processing of the 56 kDa prolegumain due to inhibition of the
HMG-CoA reductase by simvastatin. These effects of simvas-
tatin on differentiated human myotubes may contribute to the
understanding of the pharmacology and toxicology of statins.
The glucose metabolism in human myotubes decreased upon
simvastatin treatment, and it is tempting to speculate if this
could contribute to hyperglycemia, since some patients taking
statins develop decreased insulin sensitivity, insulin resistance
and glucose intolerance [10,35,36]. Furthermore, the observed
decrease in glucose uptake was prevented by concomitant
addition of mevalonolactone, suggesting that the mechanism was
due to direct inhibition of the HMG-CoA reductase. Although
no difference in expression of GLUT1 was observed after
simvastatin treatment in this study, regulation of activity or
translocation of the GLUT1 transporter or other GLUT
transporters could nevertheless account for the effects observed
but was not investigated further. Previously, simvastatin has
been reported to impair complex I and II in the respiratory
chain resulting in ROS accumulation in primary human
myotubes established from satellite cells isolated from another
source (Musculus vastus lateralis) [9]. In our study we detected no
differences in CO2-production by simvastatin in presence of
rotenone (complex I inhibitor), oligomycin A (ATP-synthase
inhibitor) or antimycin A (complex III inhibitor). Deviant
observations could be due to differences in both origin of
myotubes and methods used [9]. Surprisingly, simvastatin
reduced FCCP-induced glucose oxidation and oxidative reserve
capacity, indicating some effects of simvastatin on cell respira-
tion and mitochondrial function. Therefore, the expressions of
proteins in the respiratory chain (complex I-IV and ATP
synthase) were studied after treatment with simvastatin.
Although no statistically significant changes in the expressions
of the analyzed complexes were observed, the expressions
tended to decrease and could account for some of the effects.
There may be a link between the two effects observed of
simvastatin, impaired glucose metabolism and prolegumain
processing, as reduced supply of glucose could cause ATP-
depletion in the cell. Decreased ATP levels due to mitochon-
drial dysfunction have previously been reported in skeletal
muscle cells from patients with type 2 diabetes and in rat L6
GLUT4myc myotubes acquiring impaired glucose metabolism
[37,38]. We have recently shown that bafilomycin A1 (a strong
inhibitor of the vacuolar type H+-ATPase) also reduced the
activity of legumain [23]. Since the lysosomal H+-ATPase needs
ATP to accomplish acidic lysosomal pH [39], our results may
indicate that simvastatin could reduce the H+-ATPase activity
due to possible ATP-depletion resulting in increased lysosomal
pH and thus reduced prolegumain processing.
Extracellular glucose is reported to regulate the activity of the
cysteine proteases cathepsin B, D, L and S in human monocytes
and murine macrophage-like J774A.1 cells [24]. This, together
with our observations that simvastatin decreased glucose
metabolism in myotubes and the reported down-regulation of
legumain mRNA by atorvastatin observed in monocytes [20],
made us study the regulatory effects of simvastatin on legumain.
We observed a reduced activity of legumain caused by
simvastatin and speculated if this could be due to a
translocation from the lysosomes to the cytosol since such
translocation of legumain has been reported in apoptosis [17].
As a HMG-CoA reductase inhibitor, simvastatin blocks the rate
limiting step in the cholesterol synthesis. Cholesterol is a major
component of lipid bilayers and cholesterol removal from
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lysosomal membranes increases the permeability of especially
ions and protons, resulting in osmotic imbalance, destabilization
and potential leakage of proteins [40,41]. No lysosomal
translocation of legumain was observed using 30 mM simvastatin
and could thus not explain the reduced legumain activity
observed since the activity is expected to be abolished at neutral
cytosolic pH [12]. Cholesterol depletion has also been reported
to lead to improper subcellular compartmentalization of
phosphoinositides, which are essential for trafficking of intracel-
lular vesicles [42–44]. The delocalization of phosphatinositoles is
partly due to regulation by cholesterol of the activity of various
phosphatinositol kinases at distinct intracellular compartments
e.g. type II phosphatidylinositol 4-kinase IIa at the Golgi
membrane (PI4KIIa) [45,46]. Prolegumain needs acidic pH to
autoactivate [22]. Therefore, it is possible that some of the
effect of simvastatin on inhibition of legumain activity could be
due to dysfunctional transport of prolegumain from the Golgi to
vesicles with acidic pH, like the late endosomes/lysosomes. Also,
depletion of isoprenoids, mainly the geranylgeranyl pyrophos-
phate (GGPP) and farnesyl pyrophosphate (FPP), have been
suggested to be critical for statin-induced myopathy due to their
role in prenylation of small GTPases [5,6,47]. Inhibition of
prenylation will lead to improper intracellular trafficking since
functionally small GTPases such as Ras and Rab are essential
for targeting, tethering, uncoating and formation of intracellular
vesicles [5,47,48]. GGPP has been shown to prevent the
decreased prenylation of Rab1 GTPase by fluvastatin [6]. Here,
down-regulation of legumain activity by simvastatin was
significantly prevented by FPP or mevalonolactone (ML), but
not by GGPP, indicating that inhibition of prenylation of Rab1
GTPase may not account for the effects observed.
The activity of cysteine proteases are strictly controlled within
a cell, and uncontrolled legumain activity is associated with
serious diseases like atherosclerotic plaque instability and
malignant cancer [13,14]. A pro-survival role of legumain has
been reported in the parasite Blastocystis of which inhibition of
legumain activity is associated with increased programmed cell
death [16]. In this study legumain activity and expression were
decreased by simvastatin, but not cell viability, cell total protein
content or caspase-3 expression indicating that proteases other
than legumain are involved in statin-induced cell death. Down-
regulation of legumain could still contribute to a general
distortion of protease/kinase activity possibly leading to toxicity,
but this needs to be further investigated.
Simvastatin was introduced 5 days into myotube differentia-
tion to mimic an in vivo condition since reports have demon-
strated that toxic effects of statins mainly affect differentiated
myotubes and not myoblasts [6,9]. Simvastatin was used in our
study since this statin has the highest frequency of reported
myotoxic effects [49], and the lactone forms of statins are more
potent in causing myotoxicity [50]. The concentration of
simvastatin used in present study is in the micromolar range,
but the achieved plasma concentration after administration of a
clinical simvastatin dose is in the nanomolar range. Still, the
statin concentrations used in this study are in range with other
published in vitro experiments [50]. Since the exposure of
simvastatin in vitro must be for shorter periods of time (days)
compared to long term therapeutic in vivo use, and the primary
cell culture has limited life span, it can be argued that higher
statin concentrations are needed to detect cellular responses.
Nevertheless, in our study and as mentioned above, the
simvastatin concentrations used in this study (5–40 mM) caused
no significantly effects on cell viability, cell total protein contents
or expression of active caspase-3. In contrast, it has previously
been reported reduced myotube viability by 5 mM simvastatin
[9,51].
In conclusion, this study shows that simvastatin reduced both
glucose metabolism and legumain activity in myotubes. Both
phenomenon are of importance to fully understand the pharma-
cology and toxicology of statin treatment and needs to be further
investigated.
Supporting Information
Figure S1 Simvastatin reduced glucose uptake in myo-
tubes but not in HEK293 cells. Differentiated myotubes or
HEK293 cells were incubated for 48 h with or without 5 mM
simvastatin prior to incubation for 4 h with [14C(U)]glucose
(0.2 mM, 21.5 kBq/ml) using a multiwell trapping device.
Radioactivity was measured in cell lysates and corrected for total
proteins (n = 4–8, student t-test, *p,0.05 vs. untreated).
(TIF)
Figure S2 Effects of simvastatin on total protein content
(A) and caspase-3 expression (B) in differentiated
myotubes. Differentiated myotubes were incubated for 48 h
with or without simvastatin (5–40 mM). A. Total protein
concentrations in cell lysates were measured and normalized to
untreated control (n = 17). B. Equal amounts of total proteins
(10 mg) of cell lysates were analyzed for caspase-3 by immuno-
blotting. One representative immunoblot is shown and band
intensity analysis of procaspase-3 are normalized to untreated
control (n = 3).
(TIF)
Figure S3 Expressions of ATPase, complex I, II, III and
IV after simvastatin treatment. Differentiated myotubes
were pre-incubated for 48 h with or without (control) simvastatin
(10 or 30 mM; pooled results) prior to harvesting at day 7. Ten-
twenty mg total proteins were loaded per well and immunoblotting
using MitoProfileH Total OXPHOS Human WB Antibody
Cocktail was performed. GAPDH was used as loading control.
Quantification of immunobands are shown, corrected for GAPDH
and normalized to control (n = 7).
(TIF)
Figure S4 Characterization of legumain and cathepsin
B during differentiation of human myotubes. Myoblasts
(50,000 cells/well) were cultured and proliferated to 80–90%
confluence before start of differentiation (day 0), and cells were
harvested at day 0, 2, 5 and 7. A. Legumain and cathepsin B
activities in cell lysates were measured by cleavage of fluorogenic
peptide substrates (n = 3–4, student t-test, *p,0.05 vs. differenti-
ation day 0). B. Representative immunoblots of cell lysates are
shown. Equal amounts of total proteins (10 mg/well) were applied
to the gel and immunoblot analysis was performed. Immunoband
intensities of pro- and active forms of legumain (C) and cathepsin
B (D) were measured and normalized to differentiation day 0
(n= 3).
(TIF)
Figure S5 Localization of legumain and cathepsin B in
myotubes treated with or without simvastatin. Myotubes
were cultured, differentiated, and incubated for 48 h without
(control) or with 30 mM simvastatin prior to fixation at day 7. After
fixation, the cells were permeabilized, blocked and further
incubated with primary antibodies against legumain (green; A
and B) or cathepsin B (green; C and D) and arylsulfatase B (ARSB;
red). Secondary antibodies against the species of the primary
antibodies and DAPI (blue) were used. The cells were photo-
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graphed with identical camera and laser settings by LSM710
confocal microscopy (scale bars, 20 mm).
(TIF)
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Supplementary figure 1. Simvastatin reduced glucose uptake in myotubes but not in 
HEK293 cells. Differentiated myotubes or HEK293 cells were incubated for 48 h with or 
without (C) 5 μM simvastatin prior to incubation for 4 h with [14C(U)]glucose (0.2 mM, 21.5 
kBq/ml) using a multiwell trapping device. Radioactivity was measured in cell lysates and 
corrected for total protein within each treatment (n=4-8, student t-test, *p<0.05 vs. untreated).  
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Supplementary figure 2. Effects of simvastatin on total protein content (A) and caspase-
3 expression (B) in differentiated myotubes. Differentiated myotubes were incubated for 48 
h with or without simvastatin (5-40 μM). A. Total protein concentrations in cell lysates were 
measured and normalized to untreated control (n=17). B. Equal amounts of total proteins (10 
μg) of cell lysates were analyzed for caspase-3 by immunoblotting. One representative 
immunoblot is shown and band intensity analysis of procaspase-3 are normalised to untreated 
control (n=3). 
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Supplementary figure 3: Expression of ATPase, complex I, II, III and IV after 
simvastatin treatment. 
Differentiated myotubes were pre-incubated for 48 h with simvastatin (10 or 30 μM; pooled 
results) prior to harvesting at day 7. Ten-twenty μg total protein were loaded per well and 
immunoblotting was perfomed. Antibodies against ATPase, complex I, II, III, IV and 
GAPDH were used. GAPDH was used as loading control. Quantification of immunoband 
intensities are shown, corrected for GAPDH and normalized to control (n=7).  
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Supplementary figure 4. Characterization of legumain and cathepsin B during differentiation 
of human myotubes. 
Myoblasts (50,000 cells/well) were cultured and proliferated to 80-90 % confluence before 
start of differentiation (day 0), and cells were harvested as indicated at day 0, 2, 5 and 7. A. 
Legumain and cathepsin B activities in cell lysates were measured by cleavage of fluorogenic 
peptide substrates (n=3-4, student t-test, *p<0.05 vs. differentiation day 0). B. Representative 
immunoblots of cell lysates are shown. Equal amounts of total proteins (10 μg/well) were 
applied to the gel and immunoblot analysis were performed (Rh.leg., recombinant human 
legumain (5 ng)). Band intensity of legumain (C) and cathepsin B (D) was measured and 
normalized to differentiation day 0 (n=3). 
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Suppl. fig 5 
Supplementary figure 5. Localisation of legumain and cathepsin B in myotubes treated 
with or without simvastatin. 
Myotubes were cultured, differentiated, and incubated for 48 h without (control) or with 30 
μM simvastatin prior to fixation at day 7. After fixation, the cells were permeabilized, 
blocked and further incubated with primary antibodies against legumain (green; A and B) or 
cathepsin B (green; C and D) and arylsulfatase B (ARSB; red). Secondary antibodies against 
the species of the primary antibodies and DAPI (blue) were used. The cells were 
photographed with identical camera and laser settings by LSM710 confocal microscopy (scale 
bars, 20 μm). 
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